FREE patent keyword monitoring and additional FREE benefits. /images/triangleright (1K) REGISTER now for FREE triangleleft (1K)
Fresh Patents freshpatentsnav7_icons (5K)
browse patent apps by agents browse patent apps by inventors browse patent apps by industry browse patents by location monitor patent applications
    



USPTO Class 514  |  Browse by Industry: Previous - Next | All     monitor keywords
01/2007 | Recent  |  08: Dec | Nov | Oct | Sp | Aug | Jul | Jun | May | Apr | Mar | Feb | Jan |  | 07: D | N | O | S | A | J | J | M | A | M | F | J |  | 06: 12 | 11 | 10 | 09 | 8 | 7 | 6 | 5 | 4 | Dec | Nov |  | 2010 | 2009 |

    SEARCH:      Monitor Keywords | rss Custom RSS

Drug, bio-affecting and body treating compositions January USPTO class patent listing 01/07

Below are recently published patent applications awaiting approval from the USPTO. Recent week's RSS XML file available below.
Listing for abstract view: USPTO application #, Title, Abstract excerpt,Patent Agent. Listing format for list view: USPTO National Class full category number, title of the patent application.
  
01/25/2007 > 192 patent applications in 116 patent subcategories. USPTO class patent listing

20070021321 - Method of screening drug with the use of 67 kda laminin receptor and drug obtained thereby: It is intended to provide a novel method of screening a drug with the use of a 67 kDa laminin receptor and a drug obtained thereby. A method of screening a drug having an effect on inhibiting cell proliferation, an angiogenesis inhibitory effect, an effect of inhibiting cancer cell metastasis,... Agent: Whitham, Curtis & Christofferson & Cook, P.C.

20070021324 - Process for preparation of mixtures of polypeptides using purified hydrobromic acid: The subject invention provides an improved process for obtaining a mixture of polypeptides having nonuniform amino acid sequences, where each polypeptide consists essentially of alanine, glutamic acid, tyrosine and lysine where the resulting mixture of polypeptides comprises less than 0.3% brominated tyrosine and less than 1000 ppm metal ion impurities.... Agent: Cooper & Dunham, LLP

20070021322 - Selective resonance of chemical structures: Chemical compositions may be selectively or preferentially excited by the application of scores comprising a series of energy inputs.... Agent: Searete LLC Suite 110

20070021323 - Use of a nitroxide or a prodrug thereof in the prophylactic and therapeutic treatment of cancer: e

20070021326 - Composition and its therapeutic use: A composition having a variety of therapeutic and cosmetic uses comprises: (i) a vitamin; (ii) a metal salt that provides metal ions in vivo; and (iii) insulin or a growth hormone. Such a composition is useful for treating, for example, genetic disorders, skin diseases, cancer and viral infections.... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20070021325 - Drug formulation containing a solubilizer for enhancing solubility, absorption, and permeability: Solubility, absorption, and permeability of drugs upon oral administration are improved when the drugs are mixed and/or complexed with water-miscible organic solvents. Illustratively, the absorption of a heparin-deoxycholic acid conjugate upon oral administration is increased by mixing and/or complexing this conjugate with dimethyl sulfoxide. Other illustrative water-miscible organic solvents include... Agent: Alan J. Howarth

20070021327 - Methods and compositions for treatment of tumors using nucleic acid ligands to platelet-derived growth factor: A method is provided for treating solid tumors comprising administering a composition comprising a PDGF aptamer and a cytotoxic agent. In a preferred embodiment the PDGF aptamer is identified using the SELEX process for the Systematic Evolution of Ligands by Exponential enrichment. A method is also provided for reducing the... Agent: Swanson & Bratschun L.L.C.

20070021328 - Semi-synthetic rearranged vancomycin/desmethyl-vancomycin-based glycopeptides with antibiotic activity: Semi-synthetic glycopeptides that have antibacterial activity are based on modifications of a rearranged vancomycin or desmethyl-vancomycin scaffold, in particular, alkylation or acylation of the amino substituent on the amino-substituted sugar moiety on this scaffold with certain acyl groups; and/or conversion of the acid moiety on the macrocyclic ring of this... Agent: Novartis Vaccines And Diagnostics Inc.

20070021330 - Aza-peptide macrocyclic hepatitis c serine protease inhibitors: The present invention relates to compounds of Formula (I), or a pharmaceutically acceptable salt, ester, or prodrug, thereof, which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus... Agent: Edwards & Angell, LLP

20070021331 - Methods of using macrocyclic modulators of the ghrelin receptor: The present invention provides novel conformationally-defined macrocyclic compounds that have been demonstrated to be selective modulators of the ghrelin receptor (growth hormone secretagogue receptor, GHS-R1a and subtypes, isoforms and variants thereof). Methods of synthesizing the novel compounds are also described herein. These compounds are useful as agonists of the ghrelin... Agent: Myers Bigel Sibley & Sajovec

20070021329 - Treatment of hypersensitivity conditions: This invention relates to methods of treatment of hypersensitivity conditions such as asthma and other allergic conditions, and especially to treatment of these conditions with cyclic peptidic and peptidomimetic compounds which have the ability to modulate the activity of G protein-coupled receptors. The compounds preferably act as antagonists of the... Agent: Haynes And Boone, LLP

20070021335 - Agent for improving mental disorders: The present invention provides an agent for improving mental disorders due to cerebral dysfunction and an agent for inhibiting vascular hyperpermeability each containing a hepatocyte growth factor. The agent for improving mental disorders according to the present invention is useful in improving mental disorders, particularly decline in learning and memory... Agent: Wenderoth, Lind & Ponack, L.L.P.

20070021334 - Class iii slrp agonists for the reduction of blood vessel formation: The invention relates to the use of an agent that promotes class III SLRP activity in the manufacture of a medicament for the inhibition of blood vessel formation. In addition the invention relates to the use of an agent that promotes class III SLRP activity in the manufacture of a... Agent: Michael Best & Friedrich, LLP

20070021339 - Glp-1 pharmaceutical compositions: The present invention is directed to peptide analogues of glucagon-like peptide-1, the pharmaceutically-acceptable salts thereof, to methods of using such analogues to treat mammals and to pharmaceutical compositions useful therefore comprising said analogues.... Agent: Brian R. Morrill, Esq. Biomeasure Incorporated

20070021332 - Helminth-derived antigens having capacity of providing protection against parasites: The primary objective of the present invention is the development of new mutant forms of the Sm14 protein, for producing a greater production volume. The recombinant proteins here obtained were capable of providing protection against schistosome and fasciola infection. The level of protection of Sm14 recombinant proteins obtained in the... Agent: Caesar, Rivise, Bernstein, Cohen & Pokotilow, Ltd.

20070021337 - Novel agent for inducing apoptosis comprising msx1 or a gene encoding the same as an active ingredient: The present invention relates to a novel use of Msx1 protein or a nucleotide encoding the same for inducing apoptosis. The Msx1 of the present invention induces apoptosis through direct interaction with p53 via a homeodomain and such interaction leads to increased stability, and/or nuclear localization of p53 in cells.... Agent: Sheridan Ross Suite 3500

20070021333 - Pharmaceutical compositions based on anticholinergics and soluble tnf receptor fusion proteins: The present invention relates to novel pharmaceutical compositions based on anticholinergics and soluble TNF receptor fusion proteins, processes for preparing them and their use in the treatment of respiratory diseases.... Agent: Edell, Shapiro & Finnan, LLC

20070021338 - Stabilised compositions of factor vii: The invention relates to chemically as well as physically stable kits and compositions comprising polypeptides, in particular Factor VII or Factor VII-related polypeptides, such that these compositions can be stored, handled and used at room temperature.... Agent: Novo Nordisk, Inc. Patent Department

20070021343 - Stabilized teriparatide solutions: A stabilized pharmaceutical composition in the form of a solution for parenteral administration of a parathyroid hormone is described wherein the therapeutically active ingredient is stabilized with a buffer and a polyol. Preferred preparations contain in an aqueous solution human PTH(1-34), mannitol, an acetate or tartrate buffering agent and m-cresol... Agent: Eli Lilly & Company

20070021344 - Stabilized teriparatide solutions: A stabilized pharmaceutical composition in the form of a solution for parenteral administration of a parathyroid hormone is described wherein the therapeutically active ingredient is stabilized with a buffer and a polyol. Preferred preparations contain in an aqueous solution human PTH (1-34), mannitol, an acetate or tartrate buffering agent and... Agent: Eli Lilly & Company

20070021341 - Treatment of autoimmune conditions with copolymer 1 and related copolymers: The present invention is directed to polypeptides containing at least three amino acids randomly joined in a linear array; wherein at least one of the three amino acids is an aromatic amino acid, at least one of the three amino acids is a charged amino acid and at least one... Agent: Cooper & Dunham, LLP

20070021340 - Use of blood coagulation factor xiii for treating hemophilia a: A patient having hemophilia A is treated by administering factor XIII generally in conjunction with factor VIII or desmopressin.... Agent: Novo Nordisk, Inc. Patent Department

20070021336 - Use of glp-1 and agonists thereof to prevent cardiac myocyte apoptosis: The present invention relates generally to the novel use of GLP-1, including analogs, and agonists, to prevent cardiac myocyte apoptosis. The present invention relates to methods for using GLP-1 for the treatment of conditions associated with cardiac myocyte apoptosis. The present invention further relates to improving the efficiency of cardiac... Agent: Arnold & Porter LLP (18528) Attn IPDocketing Dept.

20070021342 - Wound healing: Methods for accelerating and/or improving wound healing in a subject by administering vascular endothelial growth factor (VEGF) are provided.... Agent: Genentech, Inc.

20070021345 - Peptides antibodies directed thereagainst and methods using same for diagnosing and treating amyloid-associated diseases: Peptides having at least 2 amino acids and no more than 15 amino acids are provided. The peptides comprise amino acid sequence X-Y or Y-X, wherein X is an aromatic amino acid and Y is any amino acid other than glycine. Also provided are pharmaceutical compositions and kits including such... Agent: Martin D Moynihan Prtsi Inc

20070021346 - Peptides antibodies directed thereagainst and methods using same for diagnosing and treating amyloid-associated diseases: The subject matter described herein provides novel human glucagon-like peptide-1 (GLP-1) receptor modulators that have biological activity similar or superior to native GLP-1 peptide and thus are useful for the treatment or prevention of diseases or disorders associated with GLP activity. The described compounds include chemically modified peptides that not... Agent: Louis J. Wille Bristol-myers Squibb Company

20070021348 - Novel treatment: A method of screening compounds to identify those compounds which inhibit the Asp 2 mediated cleavage of a polypeptide or protein substrate, the method comprising: providing a reaction system comprising Asp 2 and substrate; and measuring the extent of cleavage of the substrate in the presence of test compound as... Agent: Glaxosmithkline Corporate Intellectual Property - Uw2220

20070021347 - Treatment for tumors: Where it was generally thought that the smallest breakdown products of proteins had no specific biological function on their own, it now emerges that the body may utilize the normal process of proteolytic breakdown to generate important compounds such as gene-regulatory or anti-tumor compounds. Such anti-tumor compounds are useful for... Agent: Trask Britt

20070021350 - Conjugates useful in the treatment of prostate cancer: Chemical conjugates which comprise oligopeptides, having amino acid sequences that are selectively proteolytically cleaved by free prostate specific antigen (PSA) and known cytotoxic agents are disclosed. The conjugates of the invention are characterized by attachment of the cleavable oligopeptide to the oxygen atom at the 4-position on a vinca drug... Agent: Merck And Co., Inc

20070021349 - Orthogonally protected bifunctional amino acid: The present invention concerns novel orthogonally protected amino acids, there production and use for the synthesis of binding compounds usable in the diagnosis and treatment of proliferative diseases, in particular tumor diseases.... Agent: Millen, White, Zelano & Branigan, P.C.

20070021351 - Liver/plasma concentration ratio for dosing hepatitis c virus protease inhibitor: Compositions and therapeutic combinations are provided including at least one compound selected from the group consisting of compounds of Formulae I to XXVI as defined herein as well as methods of treatment, prevention or amelioration of one or more symptoms of hepatitis C, treating disorders associated with HCV virus, modulating... Agent: Schering-plough Corporation Patent Department (k-6-1, 1990)

20070021352 - Prevention and treatment of hearing disorders: Compositions, and methods of use thereof, are provided for the prevention, treatment or alleviation of symptoms of hearing are provided. Embodiments of the methods employ zonisamide as the sole active pharmaceutical agent or a combination of zonisamide and another pharmaceutical agent, such as an antioxidant, a NMDA antagonist, an SSRI... Agent: Wilson Sonsini Goodrich & Rosati

20070021353 - Alpha ketoamide compounds as cysteine protease inhibitors: The present invention is directed to compounds that are inhibitors of cysteine proteases, in particular, cathepsins B, K, L, F, and S and are therefore useful in treating diseases mediated by these proteases. The present invention is directed to pharmaceutical compositions comprising these compounds and processes for preparing them.... Agent: Townsend And Townsend And Crew, LLP

20070021354 - Hiv protease inhibitors, compositions containing the same, their pharmaceutical uses and materials for their synthesis: where the formula variables are as defined herein, are disclosed that advantageously inhibit or block the biological activity of the HIV protease. These compounds, as well as pharmaceutical compositions containing these compounds, are useful for treating patients or hosts infected with the HIV virus. Intermediates and synthetic methods for preparing... Agent: Fitzpatrick Cella Harper & Scinto

20070021355 - Antidepressants or foods and beverage for antidepression: (wherein R1, R2, R3 and R4, which may be the same or different, each represent a hydrogen atom, substituted or unsubstituted lower alkyl, or the like; R5 represents a hydrogen atom, hydroxy, or the like; R6 represents a hydrogen atom, or the like; R7 represents a hydrogen atom or substituted... Agent: Antonelli, Terry, Stout & Kraus, LLP

20070021356 - Preemptive prophlyaxis of migraine: A method of preventing the headache phase of migraine in a human comprises administration of an anti-convulsant medication to said human exhibiting prodrome symptoms of migraine. Suitably, the method comprises administration of a migraine headache phase-preventing effective amount of the anti-convulsant. There is also disclosed a pharmaceutical composition for the... Agent: Husch & Eppenberger, LLC

20070021357 - Treatment of inflammatory conditions: The invention relates to methods of inhibiting production and function of 3-deoxyglucosone and other alpha-dicarbonyl sugars in skin thereby treating or prevention various diseases, disorders or conditions. Additionally, the invention relates to treatment of various diseases, disorders or conditions associated with or mediated by oxidative stress since 3DG induces ROS... Agent: Drinker Biddle & Reath Attn: Intellectual Property Group

20070021358 - Localized delivery of cardiac inotropic agents: The present invention provides novel methods for the localized delivery of inotropic agents to the heart, including specific regions of the heart, such as the ventricles, for example in a subject undergoing cardiothoracic surgery, with the aim of supporting the myocardial contractile function of the heart.... Agent: Ronald I. Eisenstein Nixon Peabody LLP

20070021359 - Addition salts of azithromycin and citric acid and process for preparing them: Said addition salts have a molar ratio between azithromycin and citric acid such as to provide a pH comprised between 4.0 and 8.0 in a 10% aqueous solution. The process for preparing said salts comprises: a) dissolving azithromycin in a solvent or mixture of solvents; b) adding citric acid; and... Agent: Wolf Block Schorr And Solis-cohen LLP

20070021362 - Antisense antibacterial method and compound: A method and antisense compound for inhibiting the growth of pathogenic bacterial cells are disclosed. The compound contains no more than 12 nucleotide bases and has a targeting nucleic acid sequence of no fewer than 10 bases in length that is complementary to a target sequence containing or within 10... Agent: Perkins Coie LLP

20070021360 - Compositions, formulations and kit with anti-sense oligonucleotide and anti-inflammatory steroid and/or obiquinone for treatment of respiratory and lung disesase: A pharmaceutical composition and formulations comprise preventative, prophylactic or therapeutic amounts of an oligo(s) anti-sense to a specific gene(s) or its corresponding mRNA(s), and a glucocorticoid and/or non-glucocorticoid steroid or a ubiquinone or their salts. The agents, composition and formulations are used for treatment of ailments associated with impaired respiration,... Agent: Wilson Sonsini Goodrich & Rosati

20070021375 - Genetic modification of targeted regions of the cardiac conduction system: Disclosed are compositions, methods and systems for preventing or treating cardiac dysfunction, particularly cardiac pacing dysfunction by genetic modification of cells of targeted regions of the cardiac conduction system. In particular, a bio-pacemaker composition is delivered to cardiac cells to increase the intrinsic pacemaking rate of the cells, wherein the... Agent: Medtronic, Inc.

20070021363 - Genomic replacement therapy: Genomic Replacement Therapy uses the human genome found in mantle dentin of a patient's tooth to affect other cells of the body. Mantle Dentin cells in the developed tooth do not reproduce, therefore the DNA is “younger”. Replacing the genome with a “younger” one will hopefully create beneficial effect to... Agent: John M. Pavelchik

20070021365 - Inhibition of lysyl oxidase for treating tumor growth and diagnostics relating thereto: Disclosed are methods of identifying lysyl oxidase inhibitors and the use of such inhibitors to prevent and treat tumors, particularly metastatic tumors, alone and in combination with chemotherapeutic agents. Further disclosed is the use of lysyl oxidase levels for measuring metastatic potential and survival.... Agent: Peters Verny Jones & Schmitt, L.L.P.

20070021361 - Methods and materials for modulating trpm2: The invention relates to antisense oligonucleotides, compositions and methods useful for modulating the expression of TRPM2. The compositions comprise antisense oligonucleotides, particularly antisense oligonucleotides targeted to nucleic acids encoding TRPM2.... Agent: Fish & Richardson P.C.

20070021364 - Methods for genetic immunization: The present invention relates to methods for delivering a genetic immunogen, comprising a nucleic acid capable of expressing an antigen, optionally complexed with a polymer. The nucleic acid is delivered to the host via hydrodynamic intravascular injection resulting in expression of an encoded antigen in extravascular cells and induction of... Agent: Mirus Corporation

20070021367 - Modulation of socs-3 expression: Compounds, compositions and methods are provided for modulating the expression of SOCS-3. The compositions comprise oligonucleotides, targeted to nucleic acid encoding SOCS-3. Methods of using these compounds for modulation of SOCS-3 expression and for diagnosis and treatment of disease associated with expression of SOCS-3 are provided.... Agent: Knobbe, Martens, Olson & Bear, LLP

20070021368 - Nucleic acid and amino acid sequences relating to streptococcus pneumoniae for diagnostics and therapeutics: The invention provides isolated polypeptide and nucleic acid sequences derived from Streptococcus pneumoniae that are useful in diagnosis and therapy of pathological conditions; antibodies against the polypeptides; and methods for the production of the polypeptides. The invention also provides methods for the detection, prevention and treatment of pathological conditions resulting... Agent: Hamilton, Brook, Smith & Reynolds, P.C.

20070021369 - Nucleic acid and amino acid sequences relating to streptococcus pneumoniae for diagnostics and therapeutics: The invention provides isolated polypeptide and nucleic acid sequences derived from Streptococcus pneumoniae that are useful in diagnosis and therapy of pathological conditions; antibodies against the polypeptides; and methods for the production of the polypeptides. The invention also provides methods for the detection, prevention and treatment of pathological conditions resulting... Agent: Hamilton, Brook, Smith & Reynolds, P.C.

20070021370 - Nucleic acid and amino acid sequences relating to streptococcus pneumoniae for diagnostics and therapeutics: The invention provides isolated polypeptide and nucleic acid sequences derived from Streptococcus pneumoniae that are useful in diagnosis and therapy of pathological conditions; antibodies against the polypeptides; and methods for the production of the polypeptides. The invention also provides methods for the detection, prevention and treatment of pathological conditions resulting... Agent: Hamilton, Brook, Smith & Reynolds, P.C.

20070021371 - Nucleic acid and amino acid sequences relating to streptococcus pneumoniae for diagnostics and therapeutics: The invention provides isolated polypeptide and nucleic acid sequences derived from Streptococcus pneumoniae that are useful in diagnosis and therapy of pathological conditions; antibodies against the polypeptides; and methods for the production of the polypeptides. The invention also provides methods for the detection, prevention and treatment of pathological conditions resulting... Agent: Hamilton, Brook, Smith & Reynolds, P.C.

20070021372 - Nucleic acid and amino acid sequences relating to streptococcus pneumoniae for diagnostics and therapeutics: The invention provides isolated polypeptide and nucleic acid sequences derived from Streptococcus pneumoniae that are useful in diagnosis and therapy of pathological conditions; antibodies against the polypeptides; and methods for the production of the polypeptides. The invention also provides methods for the detection, prevention and treatment of pathological conditions resulting... Agent: Hamilton, Brook, Smith & Reynolds, P.C.

20070021373 - Nucleic acid and amino acid sequences relating to streptococcus pneumoniae for diagnostics and therapeutics: The invention provides isolated polypeptide and nucleic acid sequences derived from Streptococcus pneumoniae that are useful in diagnosis and therapy of pathological conditions; antibodies against the polypeptides; and methods for the production of the polypeptides. The invention also provides methods for the detection, prevention and treatment of pathological conditions resulting... Agent: Hamilton, Brook, Smith & Reynolds, P.C.

20070021374 - Nucleic acid and amino acid sequences relating to streptococcus pneumoniae for diagnostics and therapeutics: The invention provides isolated polypeptide and nucleic acid sequences derived from Streptococcus pneumoniae that are useful in diagnosis and therapy of pathological conditions; antibodies against the polypeptides; and methods for the production of the polypeptides. The invention also provides methods for the detection, prevention and treatment of pathological conditions resulting... Agent: Hamilton, Brook, Smith & Reynolds, P.C.

20070021366 - Structural-based inhibitors of the glutathione binding site in aldose reductase, methods of screening therefor and methods of use: Provided herein is a crystallized ternary structure of aldose reductase (AR) bound to NADPH and γ-glutamyl-S-(1,2-dicarboxyethyl)cysteinylglycine (DCEG). Also provided are specific inhibitors of glutathione-aldehyde binding to aldose reductase which are designed via at least computer modeling of the ternary AR:NADPH:DCEG structure and methods of designing and of screening the inhibitors... Agent: Benjamin Aaron Adler Adler & Associates

20070021376 - Supplement composition and method of use in enhancement of methylation process: A supplement composition for enhancement of methylation process is provided, which contains vitamin B6 (as pyridoxine HCl), folic acid, vitamin B12 (as cyanocobalamin), betaine HCl, and methylsulfonylmethane; and also contains S-adenosylmethionine. The supplement composition further includes silymarin (from milk thistle seed extract), N-acetyl L-cysteine, and cruciferious blend which includes broccoli... Agent: Melvin K. Silverman

20070021377 - Pharmaceutical composition comprising a macrolide immunomodulator: Snyergistic combination of a macrolide T-cell immunomodulator or immunosuppressant such as 33-epichloro-33-desoxyascomycin and a ceramide such as ceramide 3, LPC-9S or linoleic acid are provided, which are useful in particular in the treatment of dermatological or mucosal diseases such as atopic or contact dermatitis or dry skin, asteatotic eczema or... Agent: Novartis Corporate Intellectual Property

20070021378 - Heparin compositions and selectin inhibition: The disclosure provides in vitro and in vivo methods for identifying Heparins and Heparinoids that modulate the activity of selecting. The disclosure also provides Heparins and Heparinoids that modulate the activity of selecting. The identification and isolation of these heparin formulations has the potential to mediate a wide variety of... Agent: Buchanan, Ingersoll & Rooney LLP

20070021379 - Methylnicotinamide derivatives and formulations for treatment of lipoprotein abnormalities: The present invention is directed to nicotinamide derivatives, and their use in treating lipoprotein abnormalities, alone or in combination with a statin.... Agent: Lahive & Cockfield, LLP

20070021380 - Novel drug delivery compositions: The present invention provides for a novel molecules useful for delivery of compounds to a mammal, more particularly for the intracellular delivery of nucleotides, nucleotide analogues or compounds with a heterocyclic base. Also provided for are novel therapeutic complexes comprising novel molecules complexed with nucleotide analogues or heterogeneous or homogenous... Agent: Craig K. Sherbume

20070021381 - Method for increasing the activity of lysosomal enzymes: Method for enhancing in a mammalian cell the activity of an enzyme associated with Gaucher Disease by administering a competitive inhibitor of glucocerebrosidase in an amount effective to enhance the activity of the enzyme. Preferred compounds for use in the method are imino sugars and related compounds. In particular, C8-12-alkyl... Agent: Baker & Botts L.L.P.

20070021386 - Azole derivatives and fused bicyclic azole derivatives as therapeutic agents: This invention provides certain compounds, methods of their preparation, pharmaceutical compositions comprising the compounds, and their use in treating human or animal disorders. The compounds of the invention are useful as modulators of the interaction between the receptor for advanced glycated end products (RAGE) and its ligands, such as advanced... Agent: Kilpatrick Stockton LLP - 41305 Charles Calkins

20070021385 - Compositions and methods for wood preservation: Provided is a composition and method for the preservation of wood. The composition comprises 1) an azole and/or quaternary ammonium compound component and 2) a pyrethroid compound component such that wood treated with the composition has a greater decay resistance than wood treated to the same azole retention with the... Agent: Hodgson Russ LLP

20070021384 - Compounds for use in the treatment of infection: in which each of R8 to R10 is hydrogen, aryl, C1-6 alkyl, trialkylsilyl or acyl; R1 to R5 are individually selected from hydrogen, hydroxy, C1-6 alkoxy and acyloxy; R6 and R7 are H, C1-4 alkyl, trialkylsilyl or acyl; X is O or NR, and R is H or Me; in... Agent: Oliff & Berridge, PLC

20070021382 - Nitric oxide donors and uses thereof: Disclosed are novel NO-donating compounds, designed such that when NO is released from the compound a residue which is a naturally occurring metabolite is formed, and thus a development of tolerance to the compounds upon repetitive administration is prevented or decreased. Also disclosed are methods of preparing such NO-donating compounds,... Agent: Martin Moynihan Prtsi Inc

20070021383 - Organosilane quaternaries for acaricidal activity: A method for killing acarids on a surface is disclosed. The method includes applying a solution comprising an organosilane quaternary compound to the surface such that the surface is wet. In one example, the compound comprises an organosilane quaternary such as 3-(trimethoxysilyl)propyldimethyloctadecyl ammonium chloride. In another example, the solution further... Agent: Richard S. Ross, Esq.

20070021387 - Florfenicol prodrug having improved water solubility: The present invention discloses phosphate esters of florfenicol (prodrugs) and florfenicol analogs having superior water solubility that are hydrolyzed to florfenicol or the respective florfenicol analog in vivo, upon administration to an animal.... Agent: Schering-plough Corporation Patent Department (k-6-1, 1990)

20070021388 - Novel cyclic phosphate diesters of 1,3-propane-1-aryl diols and their use in preparing prodrugs: wherein: V and L are trans relative to one another; V is selected from group consisting of carbocyclic aryl, substituted carbocyclic aryl, heteroaryl, and substituted heteroaryl; and L is a leaving group selected from the group consisting of halogen, alkyl sulfonate, aryloxy optionally substituted with 1-2 substituents, N-containing heteroaryl, and... Agent: Sterne, Kessler, Goldstein & Fox PLLC

20070021389 - Zoledronic acid crystal forms, zoledronate sodium salt crystal forms, amorphous zoledronate sodium salt, and processes for their preparation: The invention relates to polymorphs of zoledronic acid and zoledronate sodium salts, amorphous zoledronate sodium salt, processes for making the polymorphs and amorphous zoledronate sodium salt, and pharmaceutical compositions containing the polymorphs and amorphous zoledronate sodium salt.... Agent: Kenyon & Kenyon LLP

20070021390 - Derivatives of heterocycles with 5 members, their preparation and their use as medicaments: e

20070021392 - Divided dose therapies with vascular damaging activity: The invention concerns the use of a vascular damaging agent or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for administration in divided doses for use in the production of a vascular damaging effect in a warm-blooded animal such as a human. In particular the vascular damaging... Agent: Morgan Lewis & Bockius LLP

20070021393 - New use of gabab receptor agonists: e

20070021391 - Preventive/remedy for urinary disturbance: It is intended to provide a preventive/remedy for urinary disturbance containing a compound, which shows an acetylcholine esterase inhibitory activity but substantially has no butyrylcholine esterase inhibitory activity, showing no side effect and being safe and efficacious without inhibiting the urine collection function; a preventive/remedy for dry mouth induced by... Agent: Wenderoth, Lind & Ponack, L.L.P.

20070021394 - 2-aminobicyclo[3.1.0]hexane-2,6-dicarboxylic ester derivative: [wherein R1 and R2 are identical or different, and each represents a hydrogen atom, a C1-10alkyl group or the like; X represents a hydrogen atom or a fluorine atom; Y represents —OCHR3R4 or the like (wherein R3 and R4 are identical or different, and each represents a hydrogen atom, a... Agent: Sughrue Mion, PLLC

20070021395 - Compositions for reducing the incidence of drug induced arrhythmia: In accordance with the present invention, novel methods and formulations are provided for treating and preventing the incidence of drug-induced pro-arrhythmia, including torsades de pointes. The methods and formulations comprise a combination of a drug that induces torsade de pointes, such as Class III antiarrhythmics, certain antimicrobials, antihistamines, antidepressants, antipsychotics,... Agent: The Procter & Gamble Company Intellectual Property Division

20070021396 - Oral contraception with trimegestone: The invention relates to a method for contraception comprising the administration of trimegestone to a woman of child-bearing age on at least 21 successive days, beginning on day 1 of the menstrual cycle, wherein on at least one of the at least 21 successive days the daily dose of trimegestone... Agent: Perman & Green

20070021399 - Amido-amino alcohols as therapeutic compounds: e

20070021400 - Amino alcohols as therapeutic compounds:

20070021397 - Neurocyte protective agent: A protective agent for neurons of the central nervous system and a prophylactic and/or therapeutic agent for disorders in neurons of the central nervous system is provided, each including a compound represented by donepezil hydrochloride.... Agent: Darby & Darby P.C.

20070021398 - Substituted pyrazoline compounds, their preparation and use as medicaments: The present invention relates to substituted pyrazoline compounds, methods for their preparation, medicaments comprising these compounds as well as their use for the preparation of a medicament for the treatment of humans and animals.... Agent: Banner & Witcoff

20070021401 - Metal complexes of n-heterocyclic carbenes as radiopharmaceuticals and antibiotics: e

20070021402 - Novel oral pharmaceutical suspension of cefdinir crystal: The present invention relates to a novel oral pharmaceutical suspension of Cefdinir crystal. More specifically, the present invention relates to a novel kit for preparation of an oral pharmaceutical suspension containing crystal form C Cefdinir.... Agent: C. Irvin Mcclelland Oblon, Spivak, Mcclelland, Maier & Neustadt, P.C.

20070021405 - Aryl- and heteroarylpiperidinecarboxylate-derivatives methods for their preparation and use thereof as fatty acid amido hydrolase enzyme inhibitors: in which m, n=1 to 3 and m+n=2 to 5; p=1 to 7; A=single bond or X, Y and/or Z; X=optionally substituted methylene; Y=C2-alkenylene, which is optionally substituted, or C2-alkynylene; Z=C3-7-cycloalkyl; R1 represents a group of aryl or heteroaryl type; R2 represents a hydrogen or fluorine atom or a hydroxyl,... Agent: Ross J. Oehler Sanofi-aventis U.s. LLC

20070021404 - Novel aza-ring derivatives and their use as monoamine neurotransmitter re-uptake inhibitors: This invention relates to novel aza-ring derivatives useful as monoamine neurotransmitter re-uptake inhibitors. In other aspects the invention relates to the use of these compounds in a method for therapy and to pharmaceutical compositions comprising the compounds of the invention.... Agent: Birch Stewart Kolasch & Birch

20070021403 - Piperidinylalkylcarbamate derivatives, methods for their preparation and the therapeutic use thereof as fatty acid amido hydrolase enzyme inhibitors: The present invention comprises peridinylalkylcarbamate derivatives, methods for their preparation and the therapeutic use thereof as fatty acid amido hydrolase (FAAH) enzyme inhibitors. These derivatives exert various pharmacological activities by interacting, inter alia, with cannabinoid and vanilloid receptors. By inhibiting the metabolic activity of the FAAH enzyme, compounds often responsible... Agent: Ross J. Oehler Sanofi-aventis U.s. LLC

20070021406 - New neurokinin antagonists for use as medicaments: The present application relates to internally cyclized naphthamide compounds of the formula Ia (wherein R1a, R1b, R1c, R2, R3, R4, R5, R6, R7, R8, X1, X2, Y, Z, and n are as defined herein), which are useful, for example, for antagonizing the pharmacological actions of the neurokinin 1 (NK1) receptor.... Agent: Cozen O'connor, P.C.

20070021407 - Substituted quinolines as antitumor agents: (v) a group of the formula —X1—C1-3alkyl-CO—NR18NR18—R20 where R18 is as defined above and R20 is selected from hydrogen or C1-5alkoxycarbonyl; or (vi) a heterocyclic ring. The invention also provides a process for the preparation of a compound of Formula (Ia), pharmaceutical compositions of a compound of Formula (Ia) and... Agent: Morgan Lewis & Bockius LLP

20070021408 - Aryl-and heteroaryl-substituted tetrahydrobenzazepines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin: )

20070021409 - Antiparasitic artemisinin derivatives (endoperoxides): This invention relates to the use of certain C-10 substituted derivatives of artemisinin of general formula (I) in the treatment and/or prophylaxis of diseases caused by infection with a parasite, certain novel C-10 substitued derivatives of artemisinin, processes for their preparation and pharmaceutical compositions containing such C-10 substituted derivatives. The... Agent: Jeffrey M. Greenman

20070021410 - Respiratory syncytial virus replication inhibitors: This invention concerns the use of compounds of formula (I) wherein -a1=a2-a3 =a4- is a radical of formula —CH═CH—CH═CH—, —N═CH—CH═CH—, —CH═N—CH═CH—, —CH═CH—N═CH—, —CH═CH—CH═N— wherein each hydrogen atom may optionally be substituted; Q is a radical of formulas (b-1), (b-2), (b-3), (b-4), (b-5), (b-6), (b-7), (b-8). G is a direct bond... Agent: Woodcock Washburn LLP

20070021411 - Supersaturated benzodiazepine solutions and their delivery: The invention describes supersaturated solutions of benzodiazepines, such as diazepam, glycofurol and water and their use for intranasal (NS) administration to combat various disorders.... Agent: Dorsey & Whitney LLP Intellectual Property Department

20070021412 - Treatment of gastrointestinal dysfunction and related stress with an enantiomerically-pure (s) 2,3-benzodiazepine: The present invention relates to methods of treatment for symptoms of gastrointestinal dysfunction and related stress that are frequently associated with, for example, irritable bowel syndrome. The symptoms include altered bowel motility, gastrointestinal inflammation, visceral hypersensitivity, or gastric ulcers.... Agent: Drinker Biddle & Reath Attn: Intellectual Property Group

20070021413 - Diamino alcohols as therapeutic compounds: e

20070021414 - 1-'2-(4-hydroxyphenyl)-2-hydroxyethyl!-piperidin-4-ol compounds as nmda receptor antagonists: This invention provides a compound of the formula (I), wherein R1 and R2 independently represents a hydrogen atom or the like; R3 represents an aryl group having from 6 to 10 ring carbon or the like; said aryl groups having from 6 to 10 ring carbon atoms and said heteroaryl... Agent: Warner-lambert Company

20070021415 - Pharmaceutical composition for the prevention or treatment of cerebral oedemas: i

20070021416 - Imidazo[2,1-b]-1,3,4-thiadiazole sulfonamides: This invention relates to compounds of Formula I and the use of compounds of Formula I as neuroprotective agents in the treatment of neuronal disorders of the central and peripheral nervous systems. Formula I:... Agent: Elmore Patent Law Group, PC

20070021417 - Processes for the preparation of linezolid intermediate: The present invention provides improved methods of converting R-N-(4-morpholiyl-3-fluorophenyl)-2-oxo-5-oxazolidinyl-methyl azide (III) to the intermediate S-N-(4-morpholinyl-3-fluorophenyl)-2-oxo-5-oxazolidinyl-methyl amine (II) that involve the production of fewer by-products than previous methods. The amine (II) may then be converted into linezolid (I) of high chemical purity with respect to the inactive R-enantiomer and bis-linezolid (IV),... Agent: Kenyon & Kenyon LLP

20070021419 - 2-aminophenyl-4-phenylpyrimidines as kinase inhibitors: e

20070021418 - Method of inhibiting production of osteopontin:

20070021420 - New derivatives of hydantoins, thiohydantoins, pyrimidinediones and thioxopyrimidinones, their preparation processes and their use as medicaments:

20070021421 - Measurement of gait dynamics and use of beta-blockers to detect, prognose, prevent and treat amyotrophic lateral sclerosis: The present invention, at least in part, provides methods of improved early diagnosis of neurodegenerative disease, e.g., ALS, in a subject via measurement of the gait dynamics of the subject (e.g., via the exemplary ventral plane videography methods disclosed herein). The present invention also provides for administration of a beta-adrenergic... Agent: Lahive & Cockfield, LLP

20070021424 - Aryloxyalkylcarbamate-type derivatives, preparation method thereof and use of same in therapeutics: e

20070021423 - Dual molecules containing peroxy derivative, the synthesis and therapeutic applications thereof: The invention relates to dual molecule compounds containing a peroxide derivative, to processes for the synthesis of such compounds, to pharmaceutical compositions comprising such compounds, and to methods of treatment and prevention of malaria comprising administering such compounds and such pharmaceutical compositions.... Agent: Ross J. Oehler Sanofi-aventis U.s. LLC

20070021422 - Prokineticin 1 receptor: The present invention relates to methods of monitoring the biological activity of the PK1 receptor.... Agent: Philip S. Johnson Johnson & Johnson

20070021425 - Reverse-turn mimetics and method relating thereto: Conformationally constrained compounds that mimic the secondary structure of reverse-turn regions of biologically active peptides and proteins are disclosed. Such reverse-turn mimetic structures have utility over a wide range of fields, including use as diagnostic and therapeutic agents. Libraries containing the reverse-turn mimetic structures of this invention are also disclosed... Agent: Seed Intellectual Property Law Group PLLC

20070021426 - Derivatives of heteroaryl-alkylcarbamates, methods for their preparation and use thereof as fatty acid amido hydrolase enzyme inhibitors: n

20070021427 - Novel tricyclic derivatives and their use: The present invention relates to tricyclic colchicine derivatives represented by the formulas (I) or (II), pharmaceutically acceptable salts thereof, and a method for providing an immuno-suppressive or immuno-modulating effect, an anti-proliferative effect, an anti-inflammatory effect or a method for treating cancer comprising administering to a patient an effective amount of... Agent: Buchanan, Ingersoll & Rooney PC

20070021428 - Immunomodulating heterocyclic compounds: Compounds of formula (I) are inhibitors of CD80 and useful in immunomodulation therapy: wherein R1 and R3 independently represent H; F; CI; Br; —NO2; —CN; C1-C6 alkyl optionally substituted by F or Cl; or C1-C6 alkoxy optionally substituted by F; R4 represents a carboxylic acid group (—COOH) or an ester... Agent: Banner & Witcoff

20070021429 - Condensed n-heterocyclic compounds and their use as crf receptor antagonists: The present invention provides compounds of formula (I) including stereoisomers, prodrugs and pharmaceutically acceptable salts or solvates thereof (Formula (I)) wherein the dashed line may represent a double bond; R is aryl or heteroaryl, each of which may be substituted by 1 to 4 groups J selected from: halogen, C1-C6... Agent: Smithkline Beecham Corporation Corporate Intellectual Property-us, Uw2220

20070021430 - Novel crystalline form of a phosphoric acid salt of a dipeptidyl peptidase-iv inhibitor: The present invention relates to a novel crystalline anhydrate polymorph of the dihydrogenphosphate salt of (2R)-4-oxo-4-[3-trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine as well as a process for their preparation, pharmaceutical compositions containing this novel form, and methods of use of the novel form and pharmaceutical compositions for the treatment of diabetes, obesity, and high blood... Agent: Merck And Co., Inc

20070021431 - Reverse-turn mimetics and method relating thereto: Conformationally constrained compounds that mimic the secondary structure of reverse-turn regions of biologically active peptides and proteins are disclosed. Such reverse-turn mimetic structures have utility over a wide range of fields, including use as diagnostic and therapeutic agents. Libraries containing the reverse-turn mimetic structures of this invention are also disclosed... Agent: Seed Intellectual Property Law Group PLLC

20070021432 - Treatment of mesothelioma: The present invention relates to a method of treating a warm-blooded animal, especially a human, having mesothelioma, especially malignant mesothelioma, comprising administering to said animal a therapeutically effective amount of a 4-pyridylmethyl-phthalazine derivative.... Agent: Novartis Corporate Intellectual Property

20070021433 - Pharmacological chaperones for treating obesity: The invention relates to methods of enhancing normal melanocortin-4 receptor (MC4R) activity, and to enhancing activity of an MC4R having a mutation which affects protein folding and/or processing of the MC4R. The invention provides a method of treating an individual having a condition in which increased activity of an MC4R... Agent: Baker & Botts

20070021434 - Non-nucleoside anti-hepacivirus agents and uses thereof: The present dislcosure provides amide-based, non-nucleoside compounds having antiviral activity against Hepacivirus, such as hepatitis C virus (HCV), methods and intermediates for synthesizing such compounds, and methods of using the compounds in a variety of contexts, including in the treatment and prevention of viral infections. The present dislcosure also provides... Agent: Darby & Darby P.C.

20070021435 - Aminopyrimidines as kinase modulators: where R3, B, Z, r and R1 are as defined herein, the use of such compounds as protein tyrosine kinase modulators, particularly inhibitors of FLT3 and/or c-kit and/or TrkB, the use of such compounds to reduce or inhibit kinase activity of FLT3 and/or c-kit and/or TrkB in a cell or... Agent: Philip S. Johnson Johnson & Johnson

20070021436 - Intermediates useful in the synthesis of alkylquinoline and alkylquinazoline kinase modulators, and related methods of synthesis: e

20070021437 - Substituted pyrazoles: Substituted pyrazoles, methods of manufacturing them, compositions containing them, and methods of using them to treat, for example, autoimmune diseases mediated by cathepsin S.... Agent: Philip S. Johnson Johnson & Johnson

20070021438 - Itraconazole solution: A solution for oral administration comprising itraconazole, an alcoholic solvent, and an acid.... Agent: Nixon & Vanderhye, PC

20070021440 - Inhibitors of macrophage migration inhibitory factor and methods for identifying the same: s

20070021439 - Methods of reducing risk of infection from pathogens with soluble amide and ester pyrazinoylguanidine sodium channel blockers: Prophylactic treatment methods are provided for protection of individuals and/or populations against infection from airborne pathogens. In particular, prophylactic treatment methods are provided comprising administering a sodium channel blocker or pharmaceutically acceptable salts thereof to one or more members of a population at risk of exposure to or already exposed... Agent: Hutchison Law Group PLLC

20070021441 - Fungicidal mixtures for fighting against rice pathogens: o

20070021442 - Hiv reverse transcriptase inhibitors: are HIV reverse transcriptase inhibitors, wherein A, X, Y, Z, R1 and R2 are defined herein. The compounds and their pharmaceutically acceptable salts are useful in the inhibition of HIV reverse transcriptase, the prophylaxis and treatment of infection by HIV and in the prophylaxis, delay in the onset, and treatment... Agent: Merck And Co., Inc

20070021443 - Purine and imidazopyridine derivatives for immunosuppression: The present invention provides novel purine and imidazopyridine derivatives useful for the prevention and treatment of autoimmune diseases, inflammatory disease, mast cell mediated disease and transplant rejection. The compounds are of the general formulas:... Agent: Heslin Rothenberg Farley & Mesiti PC

20070021444 - Valacyclovir polymorphs and a process for the preparation thereof: A process for the preparation of valacyclovir hydrochloride in monohydrate form, as well as of several other hydrate and anhydrous forms, and novel hydrate polymorphic forms obtainable by said process.... Agent: Mathews, Shepherd, Mckay, & Bruneau, P.A.

20070021445 - Pyridopyrimidine protein tyrosine phosphatase inhibitors: p

20070021446 - 2-arylbenzothiazole analogues and uses thereof:

20070021447 - 2-imino-4-(thio)oxo-5-poly cyclovinylazolines for use as p13 kinase ihibitors: The present invention is related to 2-imino-azolinone-vinyl fused-benzene derivatives of Formula (1) in particular for the treatment and/or prophylaxis of autoimmune disorders and/or inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, kidney diseases, platelet aggregation, cancer, transplantation, graft rejection or lung injuries.... Agent: C. Irvin Mcclelland Oblon, Spivak, Mcclelland, Maier & Neustadt, P.C.

20070021448 - Treating an inflammatory disorder or inhibiting respiratory burst in adherent neutrophils with chemical inhibitors of neutrophil activation: The present invention relates to a method of treating an inflammatory disorder in a subject with an effective amount of compound having the general formula (I) as described in the present application, under conditions effective to treat the inflammatory disorder. The present invention also relates to a method of inhibiting... Agent: Nixon Peabody LLP - Patent Group

20070021450 - Indanylamino uracils and their use as antioxidants and neuroprotectants: enantiomers, tautomers, and pharmaceutically acceptable salts of the compounds, pharmaceutical compositions containing such compounds or salts, and processes for their preparation. The subject invention also provides methods of alleviating symptoms of neurologic and inflammatory disorders, methods of preventing oxidation of lipids, proteins, or deoxyribonucleic acids on a cellular level, and... Agent: Cooper & Dunham, LLP

20070021451 - Method for preventing or treating neurologic damage after spinal cord injury: a

20070021449 - Pyrimidine derivatives for the prevention of hiv infection: This invention concerns the use of a compound for the manufacture of a medicament for the prevention of HIV infection via sexual intercourse and related intimate contact between partners, wherein the compound is a compound of formula (I) a N-oxide, a pharmaceutically acceptable addition salt, a quaternary amine and a... Agent: Philip S. Johnson Johnson & Johnson

20070021452 - Pyrimidin-4-yl-3, 4-thione compounds and their use in therapy: i

20070021453 - Novel spirochromanone derivatives:

20070021454 - Spiropiperidine beta-secretase inhibitors for the treatment of alzheimer's disease: and tautomers thereof, which are inhibitors of the beta-secretase enzyme and that are useful in the treatment of diseases in which the beta-secretase enzyme is involved, such as Alzheimer's disease. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in... Agent: Merck And Co., Inc

20070021455 - Process for the preparation of finasteride form i: A process of preparing finasteride Form (I), which process comprises dissolving finasteride in a solvent, replacing the solvent partially or substantially completely with a nonsolvent and thereafter isolating finasteride Form (I). There is also provided finasteride Form (I) prepared in accordance with the present invention, and the therapeutic use thereof... Agent: Stevens Davis Miller & Mosher

20070021456 - Aminobenzimidazole derivatives: Novel compounds of formula (I) are disclosed, where R1, R1′, L, Y, m and p have the meanings given in claim 1, which are inhibitors of tyrosine kinases, in particular, TIE-2 and Raf kinases and can be used for the treatment of tumors.... Agent: Millen, White, Zelano & Branigan, P.C.

20070021457 - Large substituent, non-phenolic opioids: v

20070021458 - Selective resonance of bodily agents: Chemical compositions may be selectively or preferentially excited by the application of scores comprising a series of energy inputs.... Agent: Searete LLC Clarence T. Tegreene

20070021459 - Pyrazole derivatives and use thereof as orexin receptor antagonists: The present invention relates to the orexin receptor antagonists compounds of the general formula (I) as well as to their isomers, salts and solvates, to the pharmaceutical compositions containing them and to the therapeutic application thereof.... Agent: Ross J. Oehler Sanofi-aventis U.s. LLC

20070021460 - Novel piperidine derivative: The present invention provides a piperidine derivative represented by the following formula or analogs thereto, which are used for agents for treating or preventing various diseases related to 5-HT7.... Agent: Nath & Associates

20070021461 - Processes for preparing anhydrous and hydrate forms of antihistaminic piperidine derivatives, polymorphs and pseudomorphs thereof: e

20070021462 - Processes for preparing anhydrous and hydrate forms of antihistaminic piperidine derivatives, polymorphs and pseudomorphs thereof:

20070021463 - Indol-3-yl-carbonyl-piperidin-benzoimidazol derivatives:

20070021464 - Methods and compositions for inhibition of angiogenesis with em-12 derivatives: The present invention comprises a group of compounds that effectively inhibit angiogenesis. More specifically, thalidomide and various related compounds such as EM-12 and its derivatives have been shown to inhibit angiogenesis and to treat disease states resulting from angiogenesis. Importantly, these compounds can be administered orally.... Agent: Jones Day

20070021465 - Anti-inflammatory compounds: Compounds of Formula (I), pharmaceutical compositions comprising compounds of Formulae (Ia) or (VII) and a method of treating a subject with an inflammatory cytokine-mediated disorder comprising administering to the subject a compound of Formulae (Ia) or (VIIa). The variables of Formulae (I), (Ia), (VII) and (VIIa) are described herein.... Agent: Hamilton, Brook, Smith & Reynolds, P.C.

20070021466 - Ccr2 inhibitors and methods of use thereof: Compounds are provided that act as potent antagonists of the CCR2 receptor. These compounds are useful for treating inflammation, a hallmark disease for CCR2. The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR2-mediated diseases, and as controls in assays for... Agent: Brinks Hofer Gilson & Lione

20070021467 - Salts of omeprazole and esomeprazole ii: The present invention relates to new salts of the single enantiomers of omeprazole, i.e. salts of (S)-5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)-methyl]sulfinyl]-1H-benzimidazole ((S)-omeprazole) and (R)-5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)-methyl]sulfinyl]-1H-benzimidazole ((R)-omeprazole) respectively. More specifically, the present invention relates to 1-cyclohexylethyl ammonium salts of the compounds, formed by a reaction of (S)-omeprazole and (R)-omeprazole respectively and 1-cyclohexylethyl amine. The present invention... Agent: White & Case LLP Patent Department

20070021468 - Preparation and use of 2-substituted-5-oxo-3-pyrazolidinecarboxylates: A method is disclosed for preparing a 2-substituted-5-oxo-3-pyrazolidinecarboxylate compound of Formula I. The method comprises contacting a succinic acid derivative of the formula R1OC(O)C(H)(X)C(R2a)(R2b)C(O)Y (i.e. Formula II) wherein X and Y are leaving groups and L, R1, R2a and R2b are as defined in the disclosure, with a substituted hydrazine... Agent: David E Heiser E I Du Pont De Nemours And Company

20070021469 - Synthesis of nicotine derivatives from nicotine: Methods of synthesizing nicotine analogs and derivatives are described. In some embodiments the methods utilize an alkyl or aryl silyl-substituted nicotine analog intermediate. Intermediates useful for the synthesis of nicotine and nicotine analogs are also described.... Agent: Myers Bigel Sibley & Sajovec

20070021472 - Benzamides and related inhibitors of factor xa: Novel benzamide compounds including their pharmaceutically acceptable isomers, salts, hydrates, solvates and prodrug derivatives having activity against mammalian factor Xa are described. Compositions containing such compounds are also described. The compounds and compositions are useful in vitro or in vivo for preventing or treating coagulation disorders.... Agent: Foley & Lardner LLP

20070021471 - Crystalline n-(2-((4-hydroxyphenyl)amino)pyridin-3-yl)-4-methoxybenzenesulfonamide ethanolates: Ethanolates of N-(2-((4-Hydroxyphenyl)amino)pyridin-3-yl)-4-methoxybenzenesulfonamide, ways to make them, compositions containing them or made with them, and methods of treating diseases using them or drugs made from them. are disclosed.... Agent: Robert Deberardine Abbott Laboratories

20070021470 - Crystalline n-(2-((4-hydroxyphenyl)amino)pyridin-3-yl)-4-methoxybenzenesulfonamide methanolates: Methanolates of N-(2-((4-Hydroxyphenyl)amino)pyridin-3-yl)-4-methoxybenzenesulfonamide, ways to make them, compositions containing them or made with them, and methods of treating diseases using them or drugs made from them are disclosed.... Agent: Robert Deberardine Abbott Laboratories

20070021473 - Novel ligand activators of the rar receptors and pharmaceutical/cosmetic applications thereof: t

20070021474 - Heterocyclically substituted benzoylureas, process for their preparation and their use as pharmaceuticals:

20070021475 - Substituted triazole derivatives: R1, R2 and R3 are as defined in the specification and to pharmaceutically suitable acid addition salts thereof. The invention includes all sterioisomeric forms, including individual diastereoisomers and enantiomers of the compound of formula (I) as well as racemic and non-racemic mixtures thereof. It has been found that the present... Agent: Hoffmann-la Roche Inc. Patent Law Department

20070021476 - Imidazo[2,1-b]-1,3,4-thiadiazole sulfonamides: This invention relates to compounds of Formula I and the use of compounds of Formula I as neuroprotective agents in the treatment of neuronal disorders of the central and peripheral nervous systems. Formula I:... Agent: Elmore Patent Law Group, PC

20070021478 - Benzothiazolyl derivatives: i

20070021477 - Cyclohexylglycine derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes: The present invention is directed to novel cyclohexylglycine derivatives which are inhibitors of the dipeptidyl peptidase-IV enzyme (“DP-IV inhibitors”) and which are useful in the treatment or prevention of diseases in which the dipeptidyl peptidase-IV enzyme is involved, such as diabetes and particularly type 2 diabetes. The invention is also... Agent: Merck And Co., Inc

20070021480 - Biologically active compounds obtainable from sorangium cellulosum: The present invention relates to a novel group of compounds having antibiotic, antifungal and/or cytostatic properties, which are obtainable from myxobacteria, especially of the genus Sorangium, preferably Sorangium cellulosum. One representative of this group of compoundsis currently named Disorazole Z and Disorazole Z-epoxide, respectively, with specific substituents and specific unsaturated... Agent: William Collard Collard & Roe, P.C.

20070021479 - Phorboxazole compounds and methods of their preparation: Novel macrolactone compounds, their methods of preparation, pharmaceutical compositions containing these compounds, and methods for their pharmaceutical use are disclosed. In certain embodiments, the macrolactone compounds may be useful, inter alia, for treating various cancers, inducing apoptosis in malignant cells, or inhibiting cancer cell division.... Agent: Woodcock Washburn LLP

20070021481 - Anti-androgenic pyrrolidines with tumor-inhibiting action: v

20070021482 - 1,5,7-trisubstituted benzimidazole derivatives and their use for modulating the gabaa receptor complex:

20070021483 - Amidine derivatives for treating amyloidosis: The present invention relates to the use of amidine compounds in the treatment of amyloid-related diseases. In particular, the invention relates to a method of treating or preventing an amyloid-related disease in a subject comprising administering to the subject a therapeutic amount of an amidine compound. Among the compounds for... Agent: Lahive & Cockfield, LLP

20070021484 - Substituted n-cinnamyl benzamides: Substituted benzamide compounds are provided along with methods for the use of those compounds for treating cancer.... Agent: Townsend And Townsend And Crew, LLP

20070021485 - Aryl (or heteroaryl) azolylcarbinols: b

20070021486 - Derivatives of n-' (1,5-diphenyl-1h-pyrazol-3-yl) sulfonamide with cb1 receptor affinity:

20070021487 - Azabicyclo derivatives as muscarinic receptor antagonists: This invention generally relates to muscarinic receptor antagonists of formula (I) which are useful, among other uses, for the treatment of various diseases of the respiratory, urinary and gastrointestinal systems mediated through muscarinic receptors. Specifically, the invention relates to derivatives of azabicyclo compounds, including, for example, 6-substituted azabicyclo[3.1.0]hexanes, as well... Agent: Ranbaxy Inc.

20070021488 - Method for treating nervous system disorders and conditions: i

20070021489 - Fibrinogen receptor antagonists and their use: wherein the symbols are defined herein, to pharmaceutical compositions containing the compounds, processes for preparing the compounds, and to methods of using the compounds, alone or in combination with other therapeutic agents. The compounds are antagonists of the platelet glycoprotein IIb/IIIa fibrinogen receptor complex, and are therefore useful for the... Agent: Volpe And Koenig, P.C.

20070021490 - Process for manufacture of pure (2s, 3as, 7as)-1-[(2s)-2-[[(1s)-1-(ethoxycarbonyl) butyl] amino]-1-oxopropyl] octahydro-1h-indole-2-carboxylic acid and its tert. butyl amine salt: New compounds useful as synthetic intermediates to synthesize perindopril, a new process for synthesizing perindopril, and new salts of perindopril.... Agent: Pharmaceutical Patent Attorneys, LLC

20070021491 - Use of inhibitors of the renin-angiotensin system in the prevention of cardiovascular events: Use of an inhibitor of the renin-angiotensin system or a pharmaceutically acceptable derivative thereof, optionally together with another antihypertensive, a cholesterol lowering agent, a diuretic or aspirin, in the manufacture of a medicament for the prevention of cardiovascular events; a method of preventing cardiovascular events comprising administering to a patient... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20070021493 - Mediators of hedgehog signaling pathways, compositions and uses related thereto: The present invention makes available methods and reagents for inhibiting aberrant growth states resulting from hedgehog gain-of-function by contacting the cell with a hedgehog antagonist, such as a small molecule, in a sufficient amount to aberrant growth state, e.g., to agonize a normal ptc pathway or antagonize hedgehog activity.... Agent: Fish & NeaveIPGroup Ropes & Gray LLP

20070021492 - Sulfamatet benzothiophene derivatives as steroid sulfatase inhibitors: The present invention relates to sulfamate benzothiophene compounds of the formula: (I) wherein R1, R2, R3, m and n are as defined in the specification. The invention also relates to pharmaceutical compositions containing these compounds and to methods of using them.... Agent: Dennison, Schultz & Macdonald

20070021494 - 3,4-di-substituted cyclobutene-1,2-diones as cxc-chemokine receptor ligands: e

20070021495 - Sulfonamides as selective estrogen receptor:

20070021496 - Methods and compositions for diagnosing and treating arthritic disorders and regulating bone mass: The present invention relates to improved diagnostic methods for early detection of a risk for developing an arthritic disorder in humans, and screening assays for therapeutic agents useful in the treatment of arthritic disorders, by comparing the levels of one or more indicators of altered mitochondrial function. Indicators of altered... Agent: Seed Intellectual Property Law Group PLLC

20070021497 - Vitamin e compositions: A Vitamin E composition containing tocotrienols (alpha-tocotrienol, beta-tocotrienol, gamma-tocotrienol, and delta-tocotrienol), and tocopherols comprising at least alpha-tocopherol and gamma-tocopherol, where the gamma-tocopherol is present in an amount greater than the alpha-tocopherol. The composition may take the form of any conventional delivery mechanism, with softgel capsules being a preferred form.... Agent: Patent Group Attn: J. Kenneth Joung

20070021498 - Novel tricyclic spiroderivatives as modulators of chemokine receptor activity: The invention provides compounds of formula (I) wherein m, R1, n, R2, q, X, Y, Z, R3, R4, R5, R6, R7, R8, t and R9 are as defined in the specification, processes for their preparation, pharmaceutical compositions containing them and their use in therapy.... Agent: Fish & Richardson P.C.

20070021499 - Crystalline base of escitalopram and orodispersible tablets comprising escitalopram base: The present invention relates to the crystalline base of the well known antidepressant drug escitalopram, S-1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-5-isobenzofurancarbonitrile, formulations of said base, a process for the preparation of purified salts of escitalopram, such as the oxalate, using the base, the salts obtained by said process and formulations containing such salts, and a... Agent: Darby & Darby P.C.

20070021500 - Methods for neuroprotection: wherein phenyl is substituted at X with one to five halogen atoms selected from the group consisting of fluorine, chlorine, bromine and iodine; and, R1, R2, R3, R4, R5 and R6 are independently selected from the group consisting of hydrogen and C1-C4 alkyl; wherein C1-C4 alkyl is optionally substituted with... Agent: Philip S. Johnson Johnson & Johnson

20070021501 - Methods of treating epileptogenesis: wherein phenyl is substituted at X with one to five halogen atoms selected from the group consisting of fluorine, chlorine, bromine and iodine; and, R1, R2, R3, R4, R5 and R6 are independently selected from the group consisting of hydrogen and C1-C4 alkyl; wherein C1-C4 alkyl is optionally substituted with... Agent: Philip S. Johnson Johnson & Johnson

20070021502 - Aniline sulfonamide derivatives and their uses: e

20070021503 - Ophthalmic fluid: An ophthalmic fluid containing at least one triglyceride, diglyceride, or monoglyceride which is chemically similar or compatible with compounds found naturally in the lipid layer of the tear film of an ocular substrate. Preferably the glycerides are derived from a fatty acid containing at least one unsaturated bond in a... Agent: Duane Morris, LLPIPDepartment

20070021504 - Composition and/or method for preventing onset and/or recurrence of cardiovascular events: Provided are composition and/or methods useful in preventing onset and/or recurrence of cardiovascular events, especially in patients who have escaped the unstable period after cardiovascular angioplasty or in hyperlipidemia patients who have been treated with HMG-CoA RI.... Agent: Birch Stewart Kolasch & Birch

20070021505 - Prevention and treatment of ophthalmic complications of diabetes: An method and formulation are provided for the prevention and treatment of adverse ocular conditions which are complications of diabetes. In one embodiment, the invention comprises administering to a person having diabetes, insulin resistance, or a risk factor for diabetes a formulation comprising a metal chelator and a transport enhancer.... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.c

20070021506 - Stress relieving composition: A composition for relieving stress and/or disorder caused by stress is provided, which composition comprises lysine and arginine as active ingredients. The lysine and arginine may be in the form of a salt. In a preferred mode, the cause of stress is any one selected from the group consisting of... Agent: C. Irvin Mcclelland Oblon, Spivak, Mcclelland, Maier & Neustadt, P.C.

20070021507 - Aqueous eye drops with accelerated intraocular migration: An aqueous eye drop comprising 2-amino-3-(4-bromobenzoyl)phenylacetic acid or its pharmacologically acceptable salt or a hydrate thereof and an organic amine (for example, aminoethylsulfonic acid or trometamol) or a salt thereof is useful as an eye drop for once a day administration for treating inflammatory diseases of the external segment or... Agent: Wenderoth, Lind & Ponack, L.L.P.

20070021508 - Method for treatment of helicobacter pylori infection and/or an associated disease: in which R1 and R2, independently, are C1-C8alkyl or H, R3 is aryl or heteroaryl, and n is 0, 1, 2, 3, 4, 5 or 6. The present invention also relates to a method for treatment of Helicobacter pylori (HP) infection or disease associated with HP infection by administering a... Agent: Andrews Kurth LLP

20070021509 - Phosphate transport inhibitors: or a pharmaceutically acceptable salt thereof. Ar1 and Ar2 are independently a substituted or unsubstituted aryl group or an optionally substituted five membered or six membered non-aromatic heterocylic group fused to an optionally substituted monocylic aryl group. W and Y are independently a covalent bond or a C1-C3 substituted or... Agent: Hamilton, Brook, Smith & Reynolds, P.C.

20070021510 - Modafinil compositions: Co-crystals and solvates of racemic, enantiomerically pure, and enantiomerically mixed modafinil are formed and several important physical properties are modulated. The solubility, dissolution, bioavailability, dose response, and stability of modafinil can be modulated to improve efficacy in pharmaceutical compositions.... Agent: Cephalon, Inc.

20070021511 - Composition comprising phytosphingosine or a derivative thereof: Provided is a composition for cancer treatment including phytosphingosine or a derivative thereof, or a pharmaceutically acceptable salt thereof as an active ingredient.... Agent: Cantor Colburn, LLP

20070021512 - Inhibition of the raf/mek/p-erk pathway for treating cancer: The invention disclosed herein provides for methods of treating cancer using inhibitors of the Raf/Mek/P-Erk 1/2 pathway. These inhibitors include B2AR agonists (such as ARA-211 (pirbuterol) and isoproterenol), adenylyl cyclase activators, cAMP analogs and Epac activators. The invention also provides methods for diagnosing cancer in an individual.... Agent: Morrison & Foerster LLP

  
01/18/2007 > 157 patent applications in 101 patent subcategories. USPTO class patent listing

20070015685 - Bone cement compositions and the like comprising an rnaiii-inhibiting peptide: RNAIII-inhibiting peptide (RIP) advantageously treats or reduces the risk of biofilm formation on implanted bone cement, thus reducing the possibility of sustained chemotherapy, hospitalization, or surgical removal of the bone cement. Unlike antibiotics, RIP eradicates biofilms without inducing resistant bacterial strains, making RIP particularly advantageous in this application. Biodegradable compositions... Agent: Merchant & Gould PC

20070015686 - Dietary supplement for enhancing skeletal muscle mass, decreasing muscle protein degradation, downregulation of muscle catabolism pathways, and decreasing catabolism of muscle cells: A dietary supplement and method for enhancing skeletal muscle mass, decreasing muscle protein degradation, downregulation of muscle catabolism pathways, and decreasing catabolism of muscle cells an individual, the supplement comprising at least source of Creatine or derivatives thereof, a source of Gypenosides or Phanoside or derivatives thereof, Creatinol-O-phosphate, and a... Agent: Kenyon & Kenyon LLP

20070015687 - Synergistic pharmaceutical combination for the prevention or treatment of diabetes: The invention refers to a synergistic pharmaceutical combination which comprises (a) a first pharmaceutical composition containing an antidiabetic or anti-hyperlipidemic active agent and one or more conventional carrier(s), and (b) a second pharmaceutical composition containing a hydroximic acid derivative of the formula I and one or more conventional carrier(s). The... Agent: Birch Stewart Kolasch & Birch

20070015689 - Complexation of metal ions with polypeptides: Formulations and methods are provided for improving the stability upon exposure to aqueous media of polypeptides present in non-aqueous suspension vehicles. In particular aspects of the invention, formulations are provided that comprise a complex of a metal ion and a polypeptide suspended in a non-aqueous, biocompatible suspension vehicle. Aggregation of... Agent: Woodcock Washburn LLP

20070015688 - Method for screening for inhibitors of alzheimer's disease: This invention relates to compounds which have the ability to act as agonists for the binding of divalent copper ions to amyloid precursor protein (APP) and to methods of identifying such compounds by using the three-dimensional structure of the copper-binding domain of APP.... Agent: Leopold Presser Scully Scott Murphy & Presser

20070015690 - Cyclosporin compositions: A composition comprising from about 0.001% to about 0.4% cyclosporin A, a surfactant, and an oil having a specific gravity from 0.8 to 0.95 is disclosed herein.... Agent: Allergan, Inc.

20070015691 - Cyclosporin compositions: A composition is disclosed herein comprising from about 0.001% to about 0.4% cyclosporin A, castor oil, and a surfactant selected from the group consisting of alcohol ethoxylates, alcohols, alkyl glycosides, alkyl polyglycosides, alkylphenol ethoxylates, amine oxides, block polymers, carboxylated alcohol or alkylphenol ethoxylates, carboxylic acids/fatty acids, cellulose derivatives, ethoxylated alcohols,... Agent: Allergan, Inc.

20070015692 - Cyclosporin compositions: A composition comprising a therapeutically effective amount of cyclosporin A, a blend of oils having a specific gravity of from 0.90 to 1.07, and a surfactant is disclosed herein.... Agent: Allergan, Inc.

20070015693 - Cyclosporin compositions: Cyclosporin A compositions are disclosed herein comprising an oil and a surfactant.... Agent: Allergan, Inc.

20070015694 - Cyclosporin compositions: A composition is disclosed herein comprising from about 0.001% to about 0.4% cyclosporin A, castor oil, and a surfactant selected from the group consisting of alcohol ethoxylates, alcohols, alkyl glycosides, alkyl polyglycosides, alkylphenol ethoxylates, amine oxides, block polymers, carboxylated alcohol or alkylphenol ethoxylates, carboxylic adds/fatty acids, cellulose derivatives, ethoxylated alcohols,... Agent: Allergan, Inc.

20070015696 - 621 human secreted proteins: The present invention relates to human secreted polypeptides, and isolated nucleic acid molecules encoding said polypeptides, useful for diagnosing and treating cancer and other hyperproliferative diseases and disorders. Antibodies that bind these polypeptides are also encompassed by the present invention. Also encompassed by the invention are vectors, host cells, and... Agent: Human Genome Sciences Inc Intellectual Property Dept.

20070015703 - Adamts13-containing compositions having thrombolytic activity: This invention relates to a pharmaceutical composition having thrombolytic activity comprising ADAMTS13, and to methods for treating or preventing a disorder associated with the formation and/or the presence of one or more thrombus and to methods of disintegrating one or more thrombus in a patient in need thereof. Furthermore, the... Agent: Baxter Healthcare Corporation

20070015706 - Bifunctional variants of recombinant tissue-type plasminogen activator with platelet aggregation inhibitory activity: The present invention provides improved tPA variants having significantly reduced susceptibility to inhibition and increased affinity for platelet integrin as compared with the wild-type tPA. The present invention also provides compositions comprising the tPA variants and polynucleotides, vectors, and host cells for producing the same as well as methods of... Agent: Morgan, Lewis & Bockius LLP (sf)

20070015697 - Enhanced ocular neuroprotection and neurostimulation: An ocular method comprising non-systemic localized ocular administration of a pharmaceutically acceptable formulation and effective concentration of at least one neurostimulatory and/or neuroprotective macrolide or other agent for a duration sufficient to enhance viability, confer protection, reduce degeneration of retinal neural cells. The method is used in a patent having... Agent: Wood, Herron & Evans, LLP

20070015701 - Macromolecular conjugates of bone morphogenetic protein-7: A modified bone morphogenetic protein (BMP, also referred to as bone morphogenic protein) composition is described. The bone morphogenetic protein, in one embodiment, is BMP-7 which is chemically modified with a hydrophilic polymer, such as poly(ethylene glycol).... Agent: Perkins Coie LLP

20070015700 - Mammalian genes modulated during fasting and feeding: Genes are disclosed that are differentially-regulated during feeding and fasting cycles. These genes, and their encoded polypeptides are useful to combat obesity.... Agent: Merchant & Gould PC

20070015709 - Method for treating hemophilia b: Use of factor XIII for treating hemophilia B. A patient having hemophilia B is treated by administering factor XIII, generally in conjunction with factor IX.... Agent: Novo Nordisk, Inc. Patent Department

20070015702 - Method of treatment and/or prevention of neuropathic pain: The present invention relates to a method of treating and/or preventing neuropathic pain, comprising administering calcitonin continuously. The present invention can provide a drug effective for the treatment of various neuropathic pains. Providing a drug having an action effective on neuropathic pain and having low toxicity. An agent for treating... Agent: Edwards & Angell, LLP

20070015708 - Methods and compositions for inhibiting tumor growth and angiogenesis: The invention provides compositions comprising angiogenesis inhibitors and RGD-containing plasma adhesion proteins in a pharmaceutical carrier. This invention also provides methods of inhibiting angiogenesis, tumor growth and metastasis by administering angiogenesis inhibitors in combination with RGD-containing plasma adhesion proteins in a pharmaceutical carrier.... Agent: Knobbe Martens Olson & Bear LLP

20070015705 - Modified annexin proteins and methods for their use in platelet storage and transfusion: Modified annexin proteins, including a homodimer of human annexin V, are provided. Methods for their use, such as to prevent thrombosis without increasing hemorrhage, enhancing the survivability of platelets during storage or transfusion and to attenuate ischemia-reperfusion injury (IPI), are also provided. The modified annexins bind phosphatidylserine (PS) on cell... Agent: Swanson & Bratschun L.L.C.

20070015707 - Neuroprotective effect of activin in animals exposed to hypoxia/ischemia: This invention includes embodiments comprising activin and analogs of activin for neuronal rescue in patients having neurons that are subject to death and/or degradation as a result of neurological diseases. In certain embodiments, an activin receptor agonist can be useful for treating neuralogical diseases such as Alzheimer's Disease, Parkinson's Disease... Agent: Fliesler Meyer, LLP

20070015704 - Nucleic acid and corresponding protein entitled 238p1b2 useful in treatment and detection of cancer: A novel gene (designated 238P1B2) and its encoded protein, and variants thereof, are described wherein 238P1B2 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, 238P1B2 provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The 238P1B2 gene... Agent: Agensys C/o Morrison & Foerster LLP

20070015695 - Three-dimensional structures of tall-1 and its cognate receptors and modified proteins and methods related thereto: Disclosed are TALL-1 and TALL-1 receptor protein homologues (agonists and antagonists) designed based on the three-dimensional structure of sTALL-1, eBCMA and eBAFF-R; agonist homologues of APRIL; methods of using wild-type APRIL to inhibit the activity of TALL-1; compositions comprising such homologues, nucleic acid molecules encoding such homologues, and therapeutic methods... Agent: Sheridan Ross PC

20070015698 - Treatment of skin, and wound repair, with thymosin beta 4: Compositions and methods for treatment of skin utilizing thymosin β4.... Agent: Rothwell, Figg, Ernst & Manbeck, P.C.

20070015699 - Variants of traf2 which act as an inhibitor of tnf-alpha (tnfalpha) signaling pathway: The present invention relates to variants of TRAF2 which demonstrate the ability to inhibit the TNF α signaling pathway. In particular, applicants have isolated a splice variant of TRAF2 referred to hereinafter as “TRAF2 truncated” or “TRAF2TR” and a TRAF2 expression construct with enhanced dominant negative properties, hereafter referred to... Agent: Synnestvedt & Lechner, LLP

20070015710 - Cyclosporin compositions: A composition comprising from 0.001% to about 0.4% cyclosporin A, a surfactant, and an oil selected from the group consisting of anise oil, clove oil, cassia oil, cinnamon oil, and combinations thereof, wherein said composition is an ophthalmically acceptable emulsion is disclosed herein.... Agent: Allergan, Inc.

20070015711 - Methods for reducing oxidative damage: The invention provides a method for reducing oxidative damage in a mammal, a removed organ, or a cell in need thereof. The method comprises administering an effective amount of an aromatic cationic peptide. The aromatic cationic peptide has (a) at least one net positive charge; (b) a minimum of three... Agent: Hoffmann & Baron, LLP

20070015712 - Antimicrobial theta defensins, analogs thereof, and methods of use: The invention provides theta defensin analogs having antimicrobial activity. The invention also provides a method of reducing or inhibiting growth or survival of a microorganism in an environment capable of sustaining the growth or survival of the microorganism, comprising administering an effective amount of a theta defensin analog to the... Agent: Mcdermott, Will & Emery

20070015714 - Methods for treating fsh related conditions with gnrh antagonists: Methods for treating FSH related conditions, such as prostatic intraepithelial neoplasia, pedophilia, infertility, or vaginal bleeding, with GnRH antagonists are disclosed. The methods of the invention generally feature administering to a subject a GnRH antagonist suitable for in vivo administration and able to reduce both plasma FSH and LH levels... Agent: Lahive & Cockfield, LLP

20070015713 - Methods for treating prostate cancer: Methods are provided for treating prostate cancer, preventing or slowing proliferation of cells of prostate origin, preventing prostate cancer in a patient at risk of contracting prostate cancer, preventing or inhibiting an upregulation of the cell cycle in prostate-derived cells in a patient, and decreasing the level of prostate-specific antigen... Agent: Covington & Burling, LLP Attn: Patent Docketing

20070015715 - Method of treating cancer and neuropathic complications induced by chemotherapeutic agents using selective bradykinin b1 receptor antagonists: Aaa8 is Ile, Leu, Nle, and preferably Ile, for the treatment of metastases, cancers and/or chemotherapy-induced neuropathies, comprising the administration of said compound to a patient in need of such treatment. The present invention also relates to compositions containing such antagonists and the uses thereof.... Agent: David S. Resnick

20070015716 - Bile-acid derived compounds for enhancing oral absorption and systemic bioavailability of drugs: Disclosed are methods for providing enhanced systemic blood concentrations of orally delivered drugs that are incompletely translocated across the intestinal wall of an animal. Also disclosed are methods for the sustained release of drugs, whether poorly or readily bioavailable via oral delivery to animals. Still further, disclosed are compounds and... Agent: Buchanan, Ingersoll & Rooney PC

20070015717 - 4-[(e)-2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-napthalenyl)-1-propenyl]benzoic acid analogs and method of manufacture and use thereof: Analogs of 4-[(E)-2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-napthalenyl)-1-propenyl]benzoic acid and methods of manufacture and use thereof, such as for use in cancer prevention and treatment.... Agent: Lathrop & Clark LLP

20070015718 - Diagnosis and management of infection caused by chlamydia: The present invention provides a method of treating coronary artery disease in a patient in need thereof by administering to the patient an antichlamydial amount of a rifamycin for a duration to treat said coronary artery disease.... Agent: Clark & Elbing LLP

20070015719 - Nanoparticulate clarithromycin formulations: The present invention is directed to compositions comprising nanoparticulate macrolides such as clarithromycin, or a salt or derivative thereof, having improved bioavailability. The nanoparticulate macrolide particles of the composition have an effective average particle size of less than about 2000 nm and are useful in the treatment of infection and... Agent: Elan Drug Delivery, Inc. C/o Foley & Lardner LLP

20070015720 - Modulation of endogenous aicar levels for the treatment of diabetes and obesity: The invention relates to methods for treating type 2 diabetes, obesity, metabolic syndrome and conditions associated with these by administering an AICAR-monophosphate (AICAR-MP) enhancing agent that increases endogenous AICAR-MP levels in a cell. Inhibition of AICAR-formyltransferase activity (AICARFT) in a cell that regulates metabolic activity (such as fat, liver, muscle,... Agent: Fish & NeaveIPGroup Ropes & Gray LLP

20070015723 - Antiviral oligonucleotides having a conserved g4 core sequence: Modified oligonucleotides having a conserved G4 sequence and a sufficient number of flanking nucleotides to significantly inhibit the activity of a virus or phospholipase A2 or to modulate the telomere length of a chromosome are provided. G4 quartet oligonucleotide structures are also provided. Methods of prophylaxis, diagnostics and therapeutics for... Agent: King & Spalding LLP

20070015722 - Double stranded compositions comprising a 3'-endo modified strand for use in gene modulation: The present invention provides double stranded compositions that have a region that is complementary to a target nucleic acid. One of the targeting strand or the second strand comprises linked ribofuranosyl nucleosides and the other strand comprises linked modified nucleosides that have 3′-endo conformational geometry. The strands can be linked... Agent: Isis Pharmaceuticals, Inc

20070015721 - Hiv-gag codon-optimised dna vaccines: The invention provides a nucleotide sequence that encodes an HIV-1 gag protein or fragment thereof containing a gag epitope and a second HIV antigen or a fragment encoding an epitope of said second HIV antigen, operably linked to a heterologous promoter. Preferred polynucleotide sequences further encodes nef or a fragment... Agent: Smithkline Beecham Corporation Corporate Intellectual Property-us, Uw2220

20070015724 - Prefoldin 4 in the treatment and diagnosis of cancer: This invention provides methods employing prefoldin-4 (PFDN-4) nucleic acid and polypeptide sequences to detect cancer or a propensity to develop cancer, to monitor the efficacy of a cancer treatment, and/or for prognostic applications. Further, the invention provides methods of identifying inhibitors of PfDN-4 and methods of treating cancer by inhibiting... Agent: Townsend And Townsend And Crew, LLP

20070015725 - 2-azapurine compounds and their uses: Within oligonucleotides 2-azapurine and especially 2-azaadenine bases form specifically base pairs with guanine. This base pair is of analogous stability as an adenine-thymine but less stable than a guanine-cytosine base pair. Therefore, the incorporation of 2-azaadenine residues into oligonucleotides instead of cytosine leads specifically to hybridization complexes with nucleic acids... Agent: Quine Intellectual Property Law Group, P.C.

20070015726 - P2y6 receptor agonists for treating lung diseases: This invention is directed to a method of enhancing or facilitating the clearance of the lung mucus secretions in a subject. This invention is also directed to a method of facilitating the hydration of the lung mucus secretions in a subject. This invention is further directed to a method of... Agent: Howery LLP

20070015727 - Delivery of modulators of glutamate-mediated neurotransmission to the inner ear: The invention features methods and devices for local delivery of agents that modify glutamate-mediated neurotransmission to the inner ear for treatment of inner ear disorders caused by glutamate-induced hearing loss and/or tinnitus.... Agent: Durect Corporation Thomas P. Mccracken

20070015728 - Metered-dose and safety and compliance packaging for systemic anticancer therapy: The invention provides a metered-dose package for coadministration of a first and a second component of a therapeutic agent. The metered-dose package includes a first plurality of fluidly noncommunicating chambers, each chamber sealably containing an individual dose of the first component, and a second plurality of chambers, each said chamber... Agent: Dechert LLP

20070015729 - Conjugate of cyclodextrin and poly(oxyethylene), and process for preparation thereof: A novel cyclodextrin conjugate having poly(oxyethylene) as a spacer is non-toxic and forms highly biocompatible supramolecular structures exhibiting significant inclusive property and structural diversity, and thus, can be beneficially employed in various fields such as drug delivery, food and flavors, cosmetics, packing, textiles, separation processes, environment protection, fermentation and catalysis.... Agent: Anderson, Kill & Olick, P.C.

20070015730 - Peripherally-selective inhibitors of dopamine-ß-hydroxylase and method of their preparation: where R1, R2 and R3 are the same or different and signify hydrogens, halogens, alkyl, alkylaryl, alkyloxy, hydroxy, nitro, amino, alkylcarbonylamino, alkylamino or dialkylamino group; R4 signifies hydrogen, alkyl or alkylaryl group; X is CH2, O or S, and n is 1, 2 or 3, with the proviso that if... Agent: Rankin, Hill, Porter & Clark, LLP

20070015731 - 5,6-di-substituted oxadiazolopyrazines and thiadiazolopyrazines as cxc-chemokine receptor ligands: e

20070015732 - Adenosine receptor antagonists and methods of making and using the same:

20070015733 - Aryl phosphate derivatives of d4t having activity against resistant hiv strains: Methods of inhibiting virus replication of in a cell infected with a resistant strain of HIV that includes administering to the infected cell a virus replication inhibiting amount of an aryl phosphate derivative of d4T.... Agent: Merchant & Gould PC

20070015734 - Mao-b inhibitors useful for treating obesity: t

20070015735 - Water-dispersible carotenoids, including analogs and derivatives: A method used for synthesizing intermediates for use in the synthesis of carotenoid synthetic intermediates, carotenoid analogs, and/or carotenoid derivatives. The analog, derivative, or intermediate may be administered such that a subject's risk of experiencing diseases associated with reactive oxygen species, reactive nitrogen species, radicals and/or non-radicals may be thereby... Agent: Meyertons, Hood, Kivlin, Kowert & Goetzel, P.C.

20070015736 - Pharmaceutical products comprising bisphosphonates: A pharmaceutical product comprises a container containing a bisphosphonate solution, in which at least the internal surface of the container comprises a plastic material and in which the container is heat sterilisable, and which is in the form of a ready to use infusion solution, for administration of the bisphosphonate... Agent: Novartis Corporate Intellectual Property

20070015737 - Compounds for inhibiting diseases and preparing cells for transplantation: Methods and compositions which are useful in the treatment of amyloidosis. In particular, methods and compositions are provided for inhibiting, preventing and treating amyloid depositions, e.g. in pancreatic islets, wherein the amyloidotic deposits are islet amyloid polypeptide (IAPP)-associated amyloid deposition or deposits. The methods of the invention involved administering to... Agent: Lahive & Cockfield

20070015739 - Use of non-antibacterial tetracycline formulations for inhibiting bacterial spores: The invention relates to a method for inhibiting bacterial spores from becoming infectious vegetative cells in a mammal in need thereof. In another embodiment, invention relates to a method for inhibiting outgrowth of bacterial spores in a mammal in need thereof. The method comprises administering to the mammal an effective... Agent: Hoffmann & Baron, LLP

20070015738 - Use of non-antibacterial tetracycline formulations for inhibiting bacterial spores from becoming infectious vegetative cells: The invention relates to a method for inhibiting bacterial spores from becoming infectious vegetative cells in a mammal in need thereof. The method comprises administering to the mammal an effective amount of a non-antibacterial tetracycline formulation. In one embodiment, the non-antibacterial tetracycline formulation comprises an antibacterial tetracycline in a sub-antibacterial... Agent: Hoffmann & Baron, LLP

20070015740 - Derivative prodrugs of ethinyl estradiol: The present invention is a prodrug derivative of ethinyl estradiol according to Formula I:... Agent: Fitzpatrick Cella Harper & Scinto

20070015741 - Novel prodrugs of estradiol: The present invention is a prodrug derivative of estradiol according to Formula I:... Agent: Fitzpatrick Cella Harper & Scinto

20070015742 - Porphyrin derivatives: The present invention relates to a compound of formula (I): Formula (I) wherein one or two of A, B, C and D are each independently selected from S, O, Se and Te, and the remainder are N; a, b, c and d are each independently substituted or unsubstituted 5-membered heterocyclic... Agent: Fish & Richardson PC

20070015744 - Benzimidazolone and dihydroindolone derivatives and uses thereof: e

20070015743 - Quinazoline derivatives as antitumor agents: A quinazoline derivative of the formula (I): (A chemical formula should be inserted here—please see paper copy enclosed) Formula I wherein the substituents are as defined in the text for use in the production of an anti proliferative effect which effect is produced alone or in part by inhibiting erbB2... Agent: Morgan Lewis & Bockius LLP

20070015745 - Cyclohexyl(alkyl)propanolamines, preparation method and pharmaceutical compositions containing same: in which R represents a hydrogen or halogen atom, an —S(O)z(C1-C4)alkyl group, an —NHSO2(C1-C4)alkyl group, an —SO2NH(C1-C4)alkyl group, an —NHSO2phenyl-(C1-C4)alkyl group or an —NHSO2phenyl group, said phenyl possibly being substituted with a halogen atom, with a (C1-C4)alkyl group or with a (C1-C4)alkoxy group; R1 represents a hydrogen atom or a... Agent: Ross J. Oehler Sanofi-aventis U.s. LLC

20070015746 - Azepine derivaties as pharmaceutical agents: Compounds, compositions and methods are provided for modulating the activity of receptors and for the treatment, prevention, or amelioration of one or more symptoms of disease or disorder related to the activity of the receptors.... Agent: Mcdonnell Boehnen Hulbert @ Berghoff LLP

20070015747 - Respiratory syncytial virus replication inhibitors: m

20070015748 - Kinase inhibitors: The present invention relates to organic molecules capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation.... Agent: Robert J. Baran (t2-7h) Allergan, Inc.

20070015749 - Use of substituted pteridines for the treatment of respiratory diseases: The invention relates to the use of pteridines for the treatment of inflammatory and obstructive respiratory complaints, preferably asthma or COPD, as well as pharmaceutical compositions containing these compounds.... Agent: Michael P. Morris Boehringer Ingelheim Corporation

20070015750 - Tetrahydronaphthalene derivatives, process for their production and their use as anti-inflammatory agents: e

20070015751 - Nitro and amino substituted heterocycles as topoisomerase i targeting agents: wherein: R1-R5,“a” and X have any of the meanings defined in the specification and their pharmaceutically acceptable salts. The invention also provides pharmaceutical compositions comprising a compound of formula I, processes for preparing compounds of formula I, intermediates useful for preparing compounds of formula I, and therapeutic methods for treating... Agent: Viksnins Harris & Padys Pllp

20070015752 - Biaryl compositions and methods for modulating a kinase cascade: The invention relates to compounds and methods for modulating one or more components of a kinase cascade.... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.C.

20070015753 - Process for the preparation of a crystalline form of (s)-n [[3-(3-fluoro-4-(4-morpholinyl) phenyl]-2-oxo-5-oxazolidinyl] methyl] acetamide: A process for preparing a crystalline form of linezolid is provided comprising (a) providing a solution comprising linezolid in an organic solvent having a boiling point of less than or equal to about 150° C.; (b) adding an anti-solvent having a boiling point greater than or equal to about 50°... Agent: M. Carmen & Associates, PLLC

20070015754 - Acyl guanidines as beta-secretase inhibitors: or a stereoisomer; or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4 and R5 as defined herein, their pharmaceutical compositions and methods of use. These compounds inhibit the processing of amyloid precursor protein (APP) by β-secretase and, more specifically, inhibit the production of Aβ-peptide. The present disclosure is... Agent: Louis J. Wille Bristol-myers Squibb Company

20070015755 - Novel compounds and compositions as protease inhibitors: The present invention relates to novel N-cyanomethyl amides which are cysteine protease inhibitors, the pharmaceutically acceptable salts and N-oxides thereof, their uses as therapeutic agents and the methods of their making.... Agent: Ross J. Oehler Sanofi-aventis U.s. LLC

20070015756 - Chemical compounds: Pyrimidine derivatives, which are useful as VEGFR2 inhibitors are described herein. The described invention also includes methods of making such pyrimidine derivatives as well as methods of using the same in the treatment of hyperproliferative diseases.... Agent: Glaxosmithkline Corporate Intellectual Property, Mai B475

20070015758 - Novel benzylamine derivatives and their utility as cholesterol ester-transfer protein inhibitors: The present invention provides, among other things, new benzylamine compounds, compositions comprising benzylamine compounds, methods of making benzylamine compounds, and methods of using benzylamine compounds for treating or preventing a variety of conditions or diseases associated with lipoprotein metabolism.... Agent: Womble Carlyle Sandridge & Rice, PLLC Reddy US Therapeutics, Inc.

20070015757 - Novel glucagon antagonists/inverse agonists: Novel compounds that act to antagonize the action of the glucagon peptide hormone on the glucagon receptor. More particularly, it relates to glucagon antagonists or inverse agonists.... Agent: Novo Nordisk, Inc. Patent Department

20070015759 - Metasubstituted thiazolidinones, their manufacture and use as a drug: v

20070015760 - Intermediates useful in preparing certain pyrrolotriazine compounds and process for making such intermediates: The invention relates to 2,4-dichloropyrrolo[1,2-f][1,2,4]triazines, which are intermediates useful in preparing at least one 2,4-disubstituted pyrrolotriazine compound, and at least one method for making such intermediates.... Agent: Louis J. Wille Bristol-myers Squibb Company

20070015762 - Npy y5 antagonist: e

20070015761 - Tetrahydronaphthalene derivatives, process for their production and their use as anti-inflammatory agents:

20070015763 - Treatment of psychosis associated with parkinson's disease and subcortical dementias using a combination of an atypical antipsychotic with a dopamine agonist: This invention relates to combinations of an atypical antipsychotic, for example ziprasidone, and a dopamine agonist, kits containing such combinations, pharmaceutical compositions comprising such combinations, and methods of using such combinations to treat patients suffering from psychosis and movement disorders associated with Parkinson's disease and subcortical dementias.... Agent: Pfizer Inc

20070015764 - Inhibitors of hepatitis c virus rna-dependent rna polymerase, and compositions and treatments using the same: The present invention provides compounds of formula (4), and their pharmaceutically acceptable salts and solvates, which are useful as inhibitors of the Hepatitis C virus (HCV) polymerase enzyme and are also useful for the treatment of HCV infections in HCV-infected mammals. The present invention also provides pharmaceutical compositions comprising compounds... Agent: Pfizer Inc

20070015765 - Novel methods for inhibiting angiogenesis: Novel methods for inhibiting angiogenesis and treating diseases associated with angiogenesis are described. The methods may comprise administering to a patient an effective amount of a 1,2-dithiol-3-thione derivative or metabolite thereof. Preferred compounds for use in the methods include 5-(2-pyrazinyl)-4methyl-1,2-dithiol-3-thione (Oltipraz) and its metabolites.... Agent: Dann, Dorfman, Herrell & Skillman

20070015767 - Crystalline forms of 4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methyl-1-piperazinyl)propoxy]-3-quinolinecarbonitrile and methods of preparing the same: This invention is directed to a crystalline 4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methyl-1-piperazinyl)propoxy]-3-quinolinecarbonitrile monohydrate having an x-ray diffraction pattern wherein 2θ angles (°) of significant peaks are at about: 9.19, 11.48, 14.32, 19.16, 19.45, 20.46, 21.29, 22.33, 23.96, 24.95, 25.29, 25.84, 26.55, 27.61, and 29.51, and a transition temperature of about 109° C. to about... Agent: Fitzpatrick Cella (wyeth)

20070015766 - Quinoline derivatives as nk-3 and nk-2 antagonists: i

20070015768 - Ubiquitin ligase inhibitors and methods related thereto: The application discloses compounds that inhibit ubiquitin ligase activity. The application further discloses antiviral compounds, anticancer compounds, and compounds useful for the treatment of neurological disorders.... Agent: Fish & NeaveIPGroup Ropes & Gray LLP

20070015769 - Use of 5ht4 receptor antagonists in the prophylaxis or treatment of certain cardiovascular conditions: The invention relates to the use of a 5-HT4 receptor antagonist in the manufacture of a medicament for the prophylaxis or treatment of atrial remodelling in a mammal. Preferably, the antagonist is N-[(1-nbutyl-4-piperidinyl)methyl]-3,4-dihydro-2H-[1,3]oxazino[3,2-a]indole-10-carboxamide (SB 207266) or a pharmaceutically acceptable salt thereof. The invention also relates to the use of SB... Agent: Glaxosmithkline Corporate Intellectual Property - Uw2220

20070015770 - Automatic gearbox with infinitely-variable ratio: The invention relates to fungicidal mixtures for controlling rice pathogens. Said mixtures comprise as the active components 1) the triazolopyrimidine derivative of formula (I), and 2) metalaxyl-M of formula (II), in a synergistically effective amount. The invention also relates to a method for controlling rice pathogens using mixtures of compound... Agent: Birch Stewart Kolasch & Birch

20070015771 - Lonidamine analogs: Lonidamine analogs are useful in the treatment and prevention of cancer, benign prostatic hyperplasia, macular degeneration and prostatic intraepithelial neoplasia, or for use as an antispermatigenic agent.... Agent: Townsend And Townsend And Crew, LLP

20070015772 - Nucleoside metabolism inhibitors: The present invention provides a compound of formula (I), wherein: A is selected from N, CH and CR, where R is selected from halogen, optionally substituted alkyl, aralkyl and aryl, OH, NH2, NHR1, NR1R2 and SR3, where R1, R2 and R3 are each optionally substituted alkyl, aralkyl or aryl groups;... Agent: Amster, Rothstein & Ebenstein LLP

20070015773 - Aryl nitrile compounds and compositions and their uses in treating inflammatory and related disorders: Compounds, compositions and methods that are useful in the treatment of inflammatory and immune conditions and diseases are provided herein. In particular, the invention provides aryl nitrile compounds which modulate the expression and/or function of a chemokine receptor. The subject methods are useful for the treatment of inflammatory and immunoregulatory... Agent: Jones Day

20070015774 - Quinazoline derivatives useful in cancer treatment: m

20070015775 - Heterocyclic compounds:

20070015776 - Kinase inhibitors: The present invention relates to organic molecules capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation.... Agent: Allergan, Inc.

20070015777 - Use of inhibitors of the ubiquitin proteasome pathway as a method of increasing contractility of the heart: The present invention describes novel uses for inhibitors of the ubiquitin proteasome degradative pathway. In particular it describes methods for improving cardiac function, increasing alpha myosin levels in the heart, and increasing SERCA levels in the heart. The invention also provides methods for treating cardiac hypertrophy through inhibiton of the... Agent: Fulbright & Jaworski L.L.P.

20070015778 - Gonadotropin-releasing hormone receptor antagonists and methods relating thereto: wherein R1a, R1b, R2a, R2b, R3, R4, R5, R6, R7 and X are as defined herein, including stereoisomers, prodrugs and pharmaceutically acceptable salts thereof. Also disclosed are compositions containing a compound of this invention in combination with a pharmaceutically acceptable carrier, as well as methods relating to the use thereof... Agent: Seed Intellectual Property Law Group PLLC

20070015779 - Compositions and treatments for inhibiting kinase and/or hmg-coa reductase: The present invention provides compositions of matter; kits and methods for their use in the treatment of MAP kinase-related conditions and/or HMG-CoA reductase-related conditions. In particular, the invention provides compositions for treating inflammatory and/or cardiovascular conditions in an animal subject by inhibiting p38α MAP kinase and/or HMG-CoA reductase, as well... Agent: Wilson Sonsini Goodrich & Rosati

20070015782 - Benzimidazole compound: R4, R5, R6 and R7 represent a hydrogen atom, halogen atom, C1-C6 alkyl group, C1-C6 haloalkyl group, C1-C6 alkoxy group or C1-C6 haloalkoxy group; and W1 represents a single bond, methylene or ethylene group, a salt thereof or a solvate of these.... Agent: Birch Stewart Kolasch & Birch

20070015781 - Certain substituted spirocyclic lactams and use thereof as pharmaceuticals: ,

20070015780 - Method of treating cancer with azaspirane compositions: A method of treating cancer by administering a therapeutically effective amount of a compound represented by the following Formula (I), or salt, hydrate, or solvate thereof; wherein: n represents a number from 3 to 7; m represents a number from 1 to 2; R1 and R2 independently represent a hydrogen... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.C.

20070015784 - Subsitituted 1,4,8- triazaspiro [4,5]decan-2-one compounds: m

20070015783 - Substituted 1,4,8-triazaspiro[4,5]decan-2-one compounds:

20070015785 - Crystalline micronisate, process for the manufacture thereof and use thereof for the preparation of a medicament: The invention relates to a crystalline micronisate of (1 α,2β,4β,5α,7β)-7-[(hydroxydi-2-thienylacetyl)oxy]-9,9-dimethyl-3-oxa-9-azoniatricyclo[3.3.1.02,4]nonane-bromide, processes for preparing it and its use for preparing a pharmaceutical composition, particularly for preparing a pharmaceutical composition with an anticholinergic activity.... Agent: Michael P. Morris Boehringer Ingelheim Corporation

20070015786 - Treatment of hot flashes, impulse control disorders and personality change due to a general medical condition: Selective norepinephrine reuptake inhibitors are useful for the prevention or treatment of hot flashes, vasomotor symptoms, impulse control disorders or personality change due to a general medical condition.... Agent: Eli Lilly & Company

20070015787 - Apoptosis promoters: Disclosed are compounds which inhibit the activity of anti-apoptotic protein family members, compositions containing the compounds and uses of the compounds for preparing medicaments for treating diseases during which occurs expression one or more than one of an anti-apoptotic protein family member.... Agent: Robert Deberardine Abbott Laboratories

20070015788 - Chemical compounds: Compounds of formula (I): compositions comprising them, processes for preparing them and their use in medical therapy (for example modulating CCR5 receptor activity in a warm blooded animal).... Agent: Fish & Richardson P.C.

20070015789 - Novel methods using aminobenzoic acid compounds: The invention provides safe and effective methods for treating and/or preventing gastrointestinal disorders, psychiatric disorders, learning disabilities, Tourette's syndrome, obesity, epilepsy, post-menopausal syndrome, pre-menstrual syndrome, asthma, laryngitis and/or migraines by administering to a patient in need thereof at least one aminobenzoic acid compound. The aminobenzoic acid compound can optionally be... Agent: Venable LLP

20070015790 - Luminogenic and fluorogenic compounds and methods to detect molecules or conditions: A method to detect the presence or amount of at least one molecule in a sample which employs a derivative of luciferin or a derivative of a fluorophore is provided.... Agent: Schwegman, Lundberg, Woessner & Kluth, P.A.

20070015791 - Serotonin and norepinephrine reuptake inhibitors and uses thereof: Selective dual serotonin and norepinephrine reuptake inhibitors are provided. These compounds have a lower side-effect profile and are useful in compositions and products for use in treatment of a variety of conditions including depression, fibromyalgia, anxiety, panic disorder, agorophobia, post traumatic stress disorder, premenstrual dysphoric disorder, attention deficit disorder, obsessive... Agent: Howson And Howson Cathy A. Kodroff

20070015792 - N-dihydroxyalkyl-substituted 2-oxo-imidazole derivatives: in which, R stands for a dihydroxy-substituted C1-C6 alkyl group, and Cy stands for an optionally substituted C6-C10 bi- or tri-cyclic aliphatic carbocyclic group. These compounds act as nociceptin receptor antagonist, and are useful, for example, as relievers against tolerance to narcotic analgesic, dependence on narcotic analgesic or addiction; analgesic... Agent: Merck And Co., Inc

20070015793 - Synthesis of nojirimycins:

20070015794 - Vegfr-2 and vegfr-3 inhibitory anthranilamide pyridines: VEGFR-2 and VEGFR-3 inhibitory anthranilamide pyridinamides, their production and use as pharmaceutical agents for treating diseases that are triggered by persistent angiogenesis, as well as intermediate products for the production of the compounds are described. The compounds according to the invention can be used as or in the case of... Agent: Millen, White, Zelano & Branigan, P.C.

20070015795 - Composition comprising protein material and compounds comprising non-oxidizable fatty acid entities: The present invention concerns a composition prepared from a combination of non β-oxidizable fatty acid entities and a protein material, and the use of said composition for the preparation of a pharmaceutical or nutritional composition for the prevention and/or treatment of insulin resistance, obesity, diabetes, fatty liver, hypercholesterolemia, dyslipidemia, atherosclerosis,... Agent: Ladas & Parry LLP

20070015796 - Compositions and methods for treatment of fibrosis: Methods for the treatment of fibrosis, including liver fibrosis, via administration of FXR agonists are provided.... Agent: Glaxosmithkline Corporate Intellectual Property, Mai B475

20070015798 - Efficient and stereoselective process for large scale synthesis of (3r)-3-(2,3-dihydrobenzofuran-5-yl)-1,2,3,4-tetrahydropyrrolo[3,4-b]quinolin-9-one derivatives: This invention relates to an efficient process for large scale stereoselective production of (3R)-3-(2,3-dihydrobenzofuran-5-yl)-1,2,3,4-tetrahydropyrrolo[3,4-b]quinolin-9-ones and key intermediates used for the preparation of benzofuranyl pyrroloquinolones as potent and selective PDE5 inhibitors for the treatment of erectile dysfunction, as well as pharmaceutical compositions and methods of treatment utilizing these compounds.... Agent: Philip S. Johnson Johnson & Johnson

20070015797 - Substituted acid derivatives useful as antidiabetic and antiobesity agents and method: i

20070015799 - Glyoxalase inhibitors: This invention relates to compounds of formula (I) which are glyoxalase I inhibitors, pharmaceutical salts or compositions comprising such compounds, and the use of such compositions and compounds to treat various conditions alleviated by the inhibition of glyoxalase 1. Wherein X is N or CH. R2 is H, CF3; or... Agent: Nixon & Vanderhye, PC

20070015800 - Use of a compound in providing refreshedness on waking and a method for the treatment of drowsiness therewith: There is disclosed the use of triprolidine for enabling an individual to wake refreshed after sleep and the method of treating such an individual with triprolidine. The triprolidine is administered shortly before a person wishes to fall asleep, preferably orally and most commonly in the form of a tablet containing... Agent: Nixon & Vanderhye, PC

20070015801 - N-aryl-2-oxazolidinone-5-carboxamides and their derivatives: The present invention provides antibacterial agents having the formulae I, II, and III described herein.... Agent: Warner-lambert Company

20070015802 - Inhibitors of cyclin dependent kinases and their use: wherein R1, R2, R3, R4, R5, R6, R7 and A have the meanings indicated in the claims. The invention also relates to processes for the preparation of the compounds of formula (Ia), to methods of inhibiting cyclin-dependent kinases and of inhibiting cell proliferation, to the use of the compounds of... Agent: Frommer Lawrence & Haug

20070015803 - Methods for treating diseases through interruption of protein maturation, compounds that inhibit the function of molecular chaperones such as protein disulfide isomerases or interfere with glycosylation, pharmaceutical compositions comprising them, and sc: A method of treating an infectious disease caused by a pathogen comprising administering to a subject in need thereof an effective amount of one or more compounds that inhibit the function of a molecular chaperone, wherein said compound is other than tizoxanide or nitazoxanide.... Agent: Foley And Lardner LLP Suite 500

20070015804 - Polymorph of a pharmaceutical: A new crystalline polymorph of ritonavir and methods for its use and preparation are disclosed.... Agent: Robert Deberardine Abbott Laboratories

20070015805 - Process for preparing 3-arylmethylthio- and 3-heteroarylmethylthio-4,5-dihydroisoxazoline derivatives: n

20070015806 - Novel formulation: The present invention provides a liquid formulation comprising a strobilurin fungicide, such as azoxystrobin, at least one non-ionic surfactant, at least one anionic surfactant and a solvent/carrier.... Agent: Syngenta Crop Protection , Inc. Patent And Trademark Department

20070015807 - Heteroatom-linked substituted piperidines and derivatives thereof useful as histamine h3 antagonists: R3 is H, —C(O)NH2, or alkyl, aryl, cycloalkyl, heterocycloalkyl or heteroaryl, all optionally substituted; and the remaining variables are as defined in the specification; compositions and methods of treating allergy-induced airway responses, congestion, obesity, metabolic syndrome, alcoholic fatty liver disease, hepatic steatosis, nonalcoholic steatohepatitis, cirrhosis, hepatacellular carcinoma and cognition deficit... Agent: Schering-plough Corporation Patent Department (k-6-1, 1990)

20070015810 - 5(r)-substituted pyrazoline compounds, their preparation and use as medicaments: The present invention relates to substituted pyrazoline compounds, methods for their preparation, medicaments comprising these compounds as well as their use for the preparation of a medicament for the treatment of humans and animals.... Agent: Banner & Witcoff

20070015811 - 5(s)-substituted pyrazoline compounds, their preparation and use as medicaments: The present invention relates to substituted pyrazoline compounds, methods for their preparation, medicaments comprising these compounds as well as their use for the preparation of a medicament for the treatment of humans and animals.... Agent: Banner & Witcoff

20070015812 - Factor xa inhibitors: e

20070015809 - Histone deacetylase inhibitors:

20070015808 - Pharmaceutical formulations of endo-n-(9-methyl-9-azabicyclo[3,3. 1]non-3-yl)-1-methyl-1h-indazole-3-carboxamide hydrochloride: A pharmaceutical formulation suitable for multi-dose administration comprising endo-N-(9-methyl-9-azabicyclo[3.3.1]non-3-yl)-1-methyl-1H-indazole-3-carboxanide hydrochloride, a preservative selected from the group consisting of alkyl paraben and phenol, and a buffer selected from the group consisting of acetate and phosphate buffers is disclosed.... Agent: Baxter Healthcare Corporation

20070015813 - Treatment of protein folding disorders: In certain embodiments, the invention is directed to a method for treating a protein folding disorder comprising administering to a subject a compound of the formulas disclosed. In preferred embodiments, the compounds are bis-indole compounds.... Agent: Davidson, Davidson & Kappel, LLC

20070015814 - Parp modulators and treatment of cancer: The invention relates to a method of modulating poly(ADP-ribose)polymerase-1 (PARP-1) activity in a mammal comprising administering to a mammal an effective amount of an organic aromatic compound having from 4 to about 35 carbon atoms, wherein said organic aromatic compound is capable of binding the arginine-34 moiety located in Zinc... Agent: Wilson Sonsini Goodrich & Rosati

20070015815 - Hydrazide substrate shuts down protein biosynthesis capability in cells that host a metastatic or malignant disease mechanism: The MAOI hydrazide substrate is targeted by protease cleavage in cells that host cancer, viral infections, or other malignant diseases because the hydrazide substrate (R′NHNHCOR″) simulates the peptide bonds (R′NHCOR″) that are innately targeted by protease cleavage. However cleavage of the hydrazide substrate forms a hydrazine radical which bonds to... Agent: Reuben E. Deloach

20070015817 - 4-((4-(2-pyrrolidinylethoxy)phenyl)methyl)-3-(4-(trifluoromethyl)phenyl)-7-hydroxychromen-2one, pharmaceutically acceptable salts thereof and methods of use therewith: wherein R1, X, Y and n are as defined here, are disclosed. The compounds of formula (I), wherein R1 is H, can be prepared by demethylation of the corresponding phenolic methyl ether. The compounds are useful for treating a bone-resorbing disease, cancer, arthritis or an estrogen-related condition such as breast... Agent: Jones Day

20070015816 - Degradation fragments: A pharmaceutical composition comprising a compound of formula (I) wherein X is an electron withdrawing group, Y1 is hydrogen, alkyl, alkenyl, alkynyl, aryl, heterocyclyl, —SO2R4, —CO2R4, —CONHR4 or —COR4, and each of R1, R2 and R4, which may be the same or different, is hydrogen, alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl,... Agent: Fulbright & Jaworski, LLP

20070015818 - Cyclic sulfone containing retroviral protease inhibitors: The present invention relates to cyclic sulfone moiety-containing hydroxyethylamine protease inhibitor compounds and pharmaceutical or method of use therefor, particularly as an inhibitor of HIV protease.... Agent: Banner & Witcoff

20070015819 - Novel compounds: The invention relates to thiophene carboxamides of formula (I), wherein A, R1, R2, R3, n and X are as defined in the specification, processes and intermediates used in their preparation, pharmaceutical compositions containing them and their use in therapy.... Agent: Fish & Richardson P.C.

20070015820 - Nerve regeneration promoters containing semaphorin inhibitor as the active ingredient: A low-molecular weight compound, which acts at a concentration of 10 μg/ml or below to inhibit the growth cone collapse activity of semaphorin such as semaphorin 3A, semaphorin 6C or the like and/or the nerve outgrowth inhibitory activity of semaphorin in a collagen gel and which does not substantially affect... Agent: Venable LLP

20070015821 - Synthesis and complete stereochemical assignment of psymberin/irciniastatin for use as antitumor compounds: l

20070015822 - Methods for selectively treating cox-2 mediated disorders by administering gamma-tocopherol: The present invention is based upon the novel observation of the COX-II-specific inhibitory activity of gamma-tocopherol and that by combining gamma-tocopherol with precursors of connective tissue constituents, injured or degenerated connective tissue, especially of articulated joints of animal patients, may be repaired. The method of the invention for treating a... Agent: Judy Jarecki-black, Ph.d,j.d

20070015823 - Ambruticin vs compounds: where R1, R2, R3 and R4 are as defined herein. Isolated or purified naturally occurring 20,21-dihydro ambruticin compounds. The invention also provides Sorangium cellulosum ambM, ambO, ambP, and ambS mutant strains; a recombinant Sorangium cellulosum strain that produces 24-norambruticin compounds; and a method for treating a fungal infection using a... Agent: Kosan Biosciences, Inc

20070015824 - Serotonin and norepinephrine reuptake inhibitor and uses thereof: Selective dual serotonin and norepinephrine reuptake inhibitors are provided. These compounds have a lower side-effect profile and are useful in compositions and products for use in treatment of a variety of conditions including depression, fibromyalgia, anxiety, panic disorder, agoraphobia, post traumatic stress disorder, premenstrual dysphoric disorder, attention deficit disorder, obsessive... Agent: Howson And Howson Cathy A. Kodroff

20070015825 - Use of 2,2-dimethyl-3-(2,4-dichlorophenyl)-2-oxo-1-oxaspiro[4,5]dec-3-en-4-yl butanoate in order to combat acariden: The present invention relates to the use of 2,2-dimethyl-3-(2,4-dichlorophenyl)-2-oxo-1-oxaspiro[4.5]dec-3-en-4-yl butanoate for controlling acarids in hops, kiwi fruit, soft fruit, nuts, coffee, tropical fruit, spices and conifers.... Agent: Sterne, Kessler, Goldstein & Fox PLLC

20070015826 - Application of chromium-amino acid complexes in the treatment of diabetes and other diseases: Compositions comprising chromium (III) 1:3 complexes comprising amino acids and methods of use thereof are provided.... Agent: Dann, Dorfman, Herrell & Skillman

20070015827 - Methods and compositions for treating ophthalmic conditions via serum retinol, serum retinol binding protein (rbp), and/or serum retinol-rbp modulation: Compounds that reduce serum retinol, serum RBP, and/or serum retinol-RBP levels may be used to treat ophthalmic conditions associated with the overproduction of waste products that accumulate during the course of the visual cycle. We describe methods and compositions using such compounds and their derivatives to treat, for example, the... Agent: Wilson Sonsini Goodrich & Rosati

20070015828 - Highly selective serotonin and norepinephrine dual reuptake inhibitor and use thereof: Highly selective dual serotonin and norepinephrine reuptake inhibitors are provided. These compounds have a lower side-effect profile and are useful in compositions and products for use in treatment of a variety of conditions including depression, fibromyalgia, anxiety, panic disorder, agorophobia, post traumatic stress disorder, premenstrual dysphoric disorder, attention deficit disorder,... Agent: Howson And Howson Cathy A. Kodroff

20070015829 - Derivatives of seleno-amino acids: Derivatives of seleno-alpha amino acids, particularly selenomethionine as enhanced bioavailable sources of selenium in animal diets.... Agent: Mckee, Voorhees & Sease, P.L.C

20070015830 - Use of a retinoid type compound to modulate in vivo the decoupling activity of the protein ucp2: The invention relates to the use of a compound of the retinoid type particularly retinoid acid for the preparation of a medicament capable of modulating in vivo the decoupling activity of decoupling proteins. These compounds can be used conveniently for the treatment of diseases associated to an increase or reduction... Agent: Klauber & Jackson

20070015831 - Diclofenac formulations and methods of use: Methods and formulations are provided for treating migraine and other acute pain episodes using diclofenac, and formulations of diclofenac that provide both rapid and sustained relief from acute pain. Methods and formulations are also provided for treating symptoms that often accompany migraine and acute pain such as photophobia, phonophobia, nausea... Agent: King & Spalding LLP

20070015832 - Methods of treating overactive bladder and urinary incontinence: The invention relates to methods of treating or slowing the onset of overactive bladder or urinary incontinence, or a symptom thereof selected from urinary frequency, urinary urgency, nocturia, or enuresis comprising identifying and administering to a subject in need of treatment a therapeutically effective amount of a compound according to... Agent: Myriad Genetics Inc. Intellecutal Property Department

20070015833 - Formulations of fenofibrate containing menthol: The invention provides at least a composition for the treatment of elevated levels of triglycerides, comprising a therapeutically effective amount of fenofibrate or another fibrate drug intimately associated with menthol, optionally in the presence of at least one surfactant mixture. The invention also provides a method for the treatment of... Agent: Kenyon & Kenyon LLP

20070015834 - Formulations of fenofibrate containing peg/poloxamer: The invention provides at least a composition for the treatment of elevated levels of triglycerides, comprising a therapeutically effective amount of fenofibrate or another fibrate drug intimately associated with a polyethylene glycol and a poloxamer, preferably PEG 1000 and Poloxamer 407. The invention also provides a method for the treatment... Agent: Kenyon & Kenyon LLP

20070015835 - Active substance combinations having insecticidal and acaricidal properties: The present invention relates to novel insecticidally and acaricidally active compound combinations of N2-[1,1-dimethyl-2-(methylsulphonyl)ethyl]-3-iodo-N1-{2-methyl-4-[1,2,2,2-tetrafluoro-1-(trifluoromethyl)ethyl]phenyl}phthalamide of the formula (I) and the active compounds identified in the disclosure.... Agent: Bayer Cropscience Lp Patent Department

20070015836 - Modafinil synthesis process: The invention relates to a process for preparing modafinil having a defined granulometry which comprises the steps of: a) preparing a solution of DMSAM; b) contacting the solution obtained with NH3 at a predetermined temperature and a predetermined stirring; and c) isolating the modafinil formed, wherein said temperature and said... Agent: Suzanne E Miller Woodcock Washburn

20070015837 - Treatment of cancer: The present invention provides compositions of matter, kits and methods for their use in the treatment of cancer. In particular, the invention provides compositions and methods for treating cancer in a subject by inhibiting a poly-ADP-ribose polymerase, as well as providing formulations and modes of administering such compositions.... Agent: Wilson Sonsini Goodrich & Rosati

20070015838 - Cyclopentane n-lower alkyl heptenamide-5-cis-2-(3alpha-hydroxy-5-phenylpentyl)-3, 5-dihydroxy, [1alpha, 2beta, 3alpha, 5alpha] compounds as agents for lowering intraocular pressure: e

20070015839 - Daily dosage regimen for treating diabetes, obesity, metabolic syndrome and polycystic ovary syndrome: A daily dosage regimen for treating diabetes, obesity and metabolic syndrome includes a metabolic pill and one or two biguanide hypoglycemic pills packaged together. The package can include a singe day's regiment, or can include multiple days' regimen. This provides an effective method for treating diabetes, obesity and metabolic syndrome,... Agent: Wood, Herron & Evans, LLP

20070015840 - Use of an alkyl ether of hydroxystilbene for the treatment of dry skin: The present invention relates to a method for the cosmetic treatment of dry skin or of a dry scalp, comprising the topical application to the skin or the scalp of a composition containing, in a physiologically acceptable medium, at least one alkyl ether of hydroxystilbene with a saturated or unsaturated,... Agent: C. Irvin Mcclelland Oblon, Spivak, Mcclelland, Maier & Neustadt, P.C.

20070015841 - Pharmaceutical propylene glycol solvate compositions: The invention relates to pharmaceutical compositions comprising propylene glycol solvates of APIs.... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

  
01/11/2007 > 157 patent applications in 101 patent subcategories. USPTO class patent listing

20070010422 - Compounds and compositions for delivering active agents: Compounds and compositions for the delivery of active agents are provided. Methods of administration and preparation are provided as well.... Agent: Darby & Darby P.C.

20070010423 - Compositions comprising balaglitazone and further antidiabetic compounds: Methods for the treatment of type 2 diabetes and related conditions comprising the admini-stration of balaglitazone in combination with one or more other antidiabetic compound is pro-vided together with combinations useful in said treatment.... Agent: Dr. Reddy's Laboratories, Inc.

20070010425 - Pharmaceutical compositions and methods for insulin treatment: Compositions and methods for treating a patient with insulin that combines insulin, a permeation enhancer, and a carrier that maintains an acidic pH, are disclosed.... Agent: Carella, Byrne, Bain, Gilfillan, Cecchi, Stewart & Olstein

20070010424 - Propylene glycol-containing peptide formulations which are optimal for production and for use in injection devices: The present invention relates to pharmaceutical formulations comprising a peptide and propylene glycol, to methods of preparing such formulations, and to uses of such formulations in the treatment of diseases and conditions for which use of the peptide contained in such formulations is indicated. The present invention further relates to... Agent: Novo Nordisk, Inc. Patent Department

20070010426 - Composition for preventing and treating cardiovascular disorders: A composition for preventing and treating cardiovascular disorders is disclosed. The composition includes the lactoferrin and a trivalent chromium compound. The trivalent chromium compound of the present invention is selected from a group consisting of chromium (III) chloride hexahydrate, chromium (III) chloride, chromium (III) acetate, chromium (III) sulfate, chromium picolinate,... Agent: Bacon & Thomas, PLLC

20070010427 - Use of one or more metal carriers to selectively kill mammalian cells: Compositions and methods for decreasing the viability of cells, particularly aberrant non-healthy cells, and most particularly cancer cells, are disclosed. The primary agent that causes cell death is a toxic metal atom or ion. Embodiments of the invention provide compositions and methods to ensure that the toxic metal is directed... Agent: Faegre & Benson LLP Patent Docketing

20070010428 - Inhibitors of signal transduction and activator of transcription 3: Stat3 inhibitor compounds are disclosed, wherein the compounds are structural analogs of Ac-pTyr-Leu-Pro-Gln-Thr-NH2 and bind to the SH2 domain of Stat3 under physiological conditions to inhibit a cellular signaling activity of Stat3.... Agent: Vinson & Elkins, L.L.P.

20070010429 - Phospholipid formulations and uses thereof in lung disease detection and treatment: Disclosed are methods and compositions that are useful in the detection and therapy of diseases (e.g., emphysema) and damage that afflict the lungs. In some aspects, the compositions comprise a formulation enriched for a species of phosphatidylcholine, such as palmitoylmyristoyl phosphatidylcholine (16:0/14:0PC). The compositions may further be described as lung... Agent: Jagtiani + Guttag

20070010430 - Proteoglycan isolated from cartilaginous fish and process for producing the same: There are provided a cartilage extract that can be effective even when taken in a small amount and has a clear mechanism of effective action and a method of producing the extract. Provided are an isolated proteoglycan which is derived from a water extract of cartilage of cartilaginous fish and... Agent: Fulbright & Jaworski, LLP

20070010431 - Pharmaceutical formulations and methods of treatment using the same: Pharmaceutical formulations containing at least one compound of Formulae I-XXVI herein and at least one surfactant. Pharmaceutically acceptable carriers and excipients may also be included in the formulations. The formulations of the present invention are suited for use in single unit dosages.... Agent: Schering-plough Corporation Patent Department (k-6-1, 1990)

20070010445 - Administration of hypocretin-1 for treatment of narcolepsy: The invention provides compositions and methods for treatment of sleep disorders. Such methods entail administering to the patient a therapeutically effective dosage regime of an agonist of a hypocretin 1 (Hcrt-1) receptor to a peripheral tissue of the patient, and monitoring the condition of the patient responsive to the treatment,... Agent: Townsend And Townsend And Crew, LLP

20070010437 - Amino acid based compositions for the treatment of pathological conditions distinguised by insufficient mitochondrial function: Described herein are compositions suitable for the treatment of pathological conditions distinguished by ‘insufficient or reduced mitochondrial function. The compositions comprise, as principal active ingredients, the amino acids leucine, isoleucine and valine. Preferably envisaged, as further active ingredients, are the amino acids threonine and lysine, and possibly histidine, phenylalanine, methionine,... Agent: Heslin Rothenberg Farley & Mesiti PC

20070010448 - Drug targets in candida albicans: The present invention is concerned with the identification of genes or functional fragments thereof from Candida albicans which are critical for growth and cell division and which genes may be used as selective drug targets to treat Candida albicans associated infections. Novel nucleic acid sequences from Candida albicans are also... Agent: Philip S. Johnson Johnson & Johnson

20070010432 - Heat shock protein 90 activator: This invention relates the identification of a novel co-factor (termed ‘Aha1’) that interacts with the molecular chaperone Heat shock protein 90 (Hsp90) and stimulates Hsp90 activity. Various assay methods and therapeutic applications based on this interaction are provided.... Agent: Klarquist Sparkman, LLP

20070010442 - Inhibitor of vascular endothelial cell growth factor: The vascular endothelial cell growth factor (VEGF) inhibitors of the present invention are naturally occurring or recombinantly engineered soluble forms with or without a C-terminal transmembrane region of the receptor for VEGF, a very selective growth factor for endothelial cells. The soluble forms of the receptors will bind the growth... Agent: Merck And Co., Inc

20070010440 - Local treatment of bone defects: A method of local treatment of specific bone defects such as osteoporosis or bone cysts comprises the step of local administration of a formulation comprising a fusion peptide containing a first domain comprising PTH or BMP 2 or BMP 7, and a second domain comprising a covalently crosslinkable substrate domain;... Agent: Patrea L. Pabst Pabst Patent Group LLP

20070010435 - Method for treating amyloid disease: Disclosed herein are methods for treating amyloid disease in humans by clearing amyloid peptides from one or more bodily fluids such as, e.g., blood, of a patient. In particular, the methods are based on the administration capable of binding to amyloid-beta (Aβ) or on dialysis of blood or plasma exchange... Agent: Darby & Darby P.C.

20070010449 - Method of treatment of hemorrhagic disease using a factor viia/tissue factor inhibitor: The present invention provides methods of treating hemorrhagic fevers where selective inhibitors of fVIIa/TF are used as a treatment for hemorrhagic fevers and have therapeutic effects which include ameliorating and/or preventing coagulopathy and inflammatory responses. These inhibitors include certain proteins which are part of a family termed Nematode-Extracted Anticoagulant Proteins... Agent: Robins & Pasternak

20070010447 - Methods and compounds for the treatment of mucus hypersecretion: A method of treating mucus hypersecretion, the causative factor in chronic obstructive pulmonary disease (COPD), asthma and other clinical conditions involving COPD, comprises administering a compound that inhibits exocytosis in mucus secreting cells or neurones that control or direct mucus secretion. Also described is a compound, for use in the... Agent: Sterne, Kessler, Goldstein & Fox PLLC

20070010446 - Methods for treating inflammation using thyroid stimulating hormone: Thyroid stimulating hormone has been shown to have anti-inflammatory activity. Polypeptides of thyroid stimulating hormone have a novel use as an anti-inflammatory agent as a stand-alone therapy, or in conjunction with other anti-inflammatory agents. In addition, thyroid stimulating hormone can be used to potentiate the anti-inflammatory activity of glucocorticoid treatment.... Agent: Zymogenetics, Inc. Intellectual Property Department

20070010443 - Monitoring and modulating hgf/hgfr activity: Provided are methods and compositions for the modulation of hepatocyte growth factor activity to regulate lymphatic vessel development and function. Methods and composition for the monitoring and treatment of skin disorders, lymphedema, and metastatic cancers are disclosed. Also described are methods of identifying inhibitors of hepatocyte growth factor dependent lymphangiogenesis.... Agent: Fish & Richardson PC

20070010434 - Novel compositions and methods for the treatment of immune related diseases: The present invention relates to compositions containing novel proteins and methods of using those compositions for the diagnosis and treatment of immune related diseases.... Agent: Genentech, Inc.

20070010444 - Novel mediator of neurotransmitter and psychostimulant responses: The present invention provides polypeptides (termed “egl-28 polypeptides”) that modulate neurotransmitter- and psychostimulant-induced responses. The invention also provides methods of modulating such responses, as well as and anti-egl-28 antibodies. The invention encompasses related polynucleotides, vectors, host cells, production methods, and compositions. Moreover, the invention includes methods for prescreening or screening... Agent: Quine Intellectual Property Law Group, P.C.

20070010439 - Production of human parathyroid hormone from microorganisms: The invention provides recombinant plasmids containing in DNA sequences coding for human preproparathyroid hormone. The invention further provides microorganisms, for example E. coli, transformed by these plasmids. The invention also provides a plasmid for insertion into yeast and a transformed yeast in which the plasmid contains DNA coding for parathyroid... Agent: Foley And Lardner LLP Suite 500

20070010441 - Random peptides that bind to gastro-intestinal tract (git) transport receptors and related methods: This invention relates to proteins (e.g., peptides) that are capable of facilitating transport of an active agent through a human or animal gastro-intestinal tissue, and derivatives (e.g., fragments) and analogs thereof, and nucleotide sequences coding for said proteins and derivatives. The proteins of the invention have use in facilitating transport... Agent: Morgan Lewis & Bockius LLP

20070010436 - Remedy for cardiomyopathy: The present invention provides a cardiomyopathy therapeutic agent that contains hepatocyte growth factor (HGF) and gelatin hydrogel, and gradually releases HGF, which is useful in treating cardiomyopathy.... Agent: Osha Liang L.L.P.

20070010438 - Tumor treatment using beta-sheet peptides and radiotherapy: The invention relates to the use of designed β-sheet peptides together with radiation therapy for cancer treatment. The β-sheet peptides, which were designed using portions from several α-chemokines, exhibit activity as radiosensitizing agents, and have demonstrated synergism with radiation therapy for cancer treatment. The β-sheet peptides also exhibit activity as... Agent: Mueting, Raasch & Gebhardt, P.A.

20070010433 - Use of compounds capable of inhibiting the proteolytic processing of semaphorins for prevention, treatment, diagnosis and prognosis of an invasive disease: The present invention relates to use of compounds directed to inhibiting expression and/or proteolytic processing semaphorins SEMA3E and/or sema3E and/or activation of a receptor by a proteolytic product of said semaphorins for the manufacture of a medicament for prevention, treatment diagnosis and/or prognosis of an invasive disease. The invention features... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20070010450 - Methods and compositions for the treatment of gastrointestinal disorders: Compositions and related methods for treating IBS and other gastrointestinal disorders and conditions (e.g., gastrointestinal motility disorders, functional gastrointestinal disorders, gastroesophageal reflux disease (GERD), duodenogastric reflux, Crohn's disease, ulcerative colitis, inflammatory bowel disease, functional heartburn, dyspepsia (including functional dyspepsia or nonulcer dyspepsia), gastroparesis, chronic intestinal pseudo-obstruction (or colonic pseudoobstruction), and... Agent: Fish & Richardson PC

20070010451 - Method of protecting cells against damage and pharmaceutical composition comprising leumorphin: The present invention relates to a method of protecting cells against damage caused at least in part by apoptosis, comprising administering to subjects a therapeutic dose of leumorphin having cytoprotective activity, and a pharmaceutical composition comprising an effective amount of leumorphin having a cytoprotective activity.... Agent: Jhk Law

20070010452 - Methionine aminopeptidase-2 inhibitors and methods of use thereof: The present invention provides methods of parasitic infections, thymoma, and lymphoid malignancies in a subject by administering to the subject a therapeutically effective amount of one or more of the compounds of the invention.... Agent: Lahive & Cockfield, LLP

20070010455 - Hepatitis c virus inhibitors: The present disclosure relates to tripeptide compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.... Agent: Louis J. Wille Bristol-myers Squibb Company

20070010454 - Method for treating tumor cells resulting in minimal liver toxicity: A method for treating tumor cells resulting in minimal liver toxicity. An illustrative embodiment includes a method for inhibiting growth of a tumor in a mammal, comprising contacting tumor cells which have tyrosinase activity or P450 activity with 4-t-butoxyphenol, a cytotoxic phenolic composition administered at a dose sufficient to induce... Agent: Texas Tech University Office Of Technology Transfer

20070010453 - Prodrugs of gaba analogs, compositions and uses thereof: The present invention provides prodrugs of GABA analogs, pharmaceutical compositions of prodrugs of GABA analogs and methods for making prodrugs of GABA analogs. The present invention also provides methods for using prodrugs of GABA analogs and methods for using pharmaceutical compositions of prodrugs of GABA analogs for treating or preventing... Agent: Richard F. Trecartin Dorsey & Whitney LLP

20070010456 - Therapeutic agents for low hdl-cholesterolemia: The present invention is to provide an agent for low HDL-cholesterolemia, a prophylactic and/or therapeutic antiarteriosclerosis agent as well as a method for preventing and treating low HDL-cholesterolemia, arteriosclerosis and their related diseases or disorders, with emphasis given to improvement in HDL, without resorting to genetic engineering technology. Further, the... Agent: Wenderoth, Lind & Ponack, L.L.P.

20070010457 - Caspase inhibitors and uses thereof: The present invention relates to novel classes of compounds of formula I which are caspase and TNF-alpha inhibitors. This invention also relates to pharmaceutical compositions comprising these compounds. The compounds and pharmaceutical compositions of this invention are particularly well suited for inhibiting caspase and TNF-alpha activity and consequently, can be... Agent: Fish & NeaveIPGroup Ropes & Gray LLP

20070010458 - Drugs for the arthritis treatment: e

20070010459 - Application of asiatic acid and its derivatives to treat pulmonary fibrosis: Compositions comprising asiatic acid and its derivatives and asiaticoside and the methods of use there of to treat pulmonary fibrosis are provided.... Agent: Rosenbaum & Associates

20070010461 - Core 2 glcnac-t inhibitors: m

20070010462 - Core 2 glcnac-t inhibitors iii:

20070010460 - Multiple sclerosis therapy and diagnosis: A method of treatment of Multiple Sclerosis in a subject is disclosed comprising administering to the subject a compound capable of reducing the activity of Core 2 GlcNAc-T. Also disclosed is a method of diagnosing Multiple Sclerosis in a subject and a method of determining the utility of a test... Agent: Nixon & Vanderhye, PC

20070010464 - Avermectin and praziquantel combination therapy: An antiparasitic combination therapy compising a combination of a 13-monosaccharide 5-oxime avermectin, such as selamectin, and praziquantel in a veterinarily acceptable carrier, diluent or adjuvant. Also provided is a method of treatment or prophylaxis of a parasitic infestation as well as a kit useful in the treatment or prophylaxis of... Agent: Pfizer Inc.

20070010463 - Remedies for diseases caused by strengthened vascular smooth muscle using 14-membered ring macrolid compounds: It is intended in this invention to provide novel preventives/remedies for diseases caused by the growth of vascular smooth muscles, for example, re-occlusion occurring after a ballon-dilation treatment for cardiac coronary occlusion. Namely, vascular smooth muscle growth inhibitors, cyclin-dependent kinase complex expression enhancers, preventives/remedies for diseases caused by the growth... Agent: Birch Stewart Kolasch & Birch

20070010465 - Zosuquidar, daunorubicin, and cytarabine for the treatment of cancer: The present invention relates to a method of treating patients with solid tumors, leukemias, and other malignancies using a combination of zosuquidar, daunorubicin, and cytarabine. The invention is also directed to pharmaceutical formulations comprising zosuquidar, daunorubicin, and cytarabine. The formulations are particularly effective in treating relapsed Acute Myelogenous Leukemia (AML).... Agent: Knobbe Martens Olson & Bear LLP

20070010466 - Zosuquidar, daunorubicin, and cytarabine for the treatment of cancer: The present invention relates to a method of treating patients with solid tumors, leukemias, and other malignancies using a combination of zosuquidar, daunorubicin, and cytarabine. The invention is also directed to pharmaceutical formulations comprising zosuquidar, daunorubicin, and cytarabine. The formulations are particularly effective in treating relapsed Acute Myelogenous Leukemia (AML).... Agent: Knobbe Martens Olson & Bear LLP

20070010469 - Gene products differentially expressed in cancerous cells iii: The present invention provides polynucleotides, as well as polypeptides encoded thereby, that are differentially expressed in cancer cells. These polynucleotides are useful in a variety of diagnostic and therapeutic methods. The present invention further provides methods of reducing growth of cancer cells. These methods are useful for treating cancer.... Agent: Chiron Corporation Intellectual Property - R440

20070010471 - Hiv dna vaccine: A DNA vaccines or immunogenic composition for providing an immune response against HIV without exhibiting pathogenicity in the immunized individual because of the disruption of the ability of the DNA molecules to encode for viral proteins critical in producing pathogenicity. The DNA molecule is derived by passaging a SHIV in... Agent: Polsinelli Shalton Welte Suelthaus P.C.

20070010470 - Immunomodulatory oligonucleotides: Oligonucleotides containing unthylated CpG dinucleotides and therapeutic utilities based on their ability to stimulate an immune response in a subject are disclosed. Also disclosed are therapies for treating diseases associated with immune system activation that are initiated by unthylated CpG dinucleotides in a subject comprising administering to the subject oligonucleotides... Agent: Wolf Greenfield & Sacks, PC

20070010468 - Methods and compositions for the inhibition of stat5 in prostate cancer cells: The present invention relates to compositions and methods for the treatment of prostate cancer. In certain embodiments, the invention relates to compositions and methods for the inhibition of prostate cancer cell growth, comprising inhibiting the activity of Stat5 in prostate cancer cells.... Agent: Wolf Greenfield & Sacks, PC

20070010474 - Nf-kappab oligonucleotide decoy molecules: The present invention concerns double-stranded NF-κB decoy oligodeoxynucleotide (NF-κB dsODN) molecules that contain a core sequence capable of specific binding to an NF-κB transcription factor. In a particular aspect, the invention concerns NF-κB decoy molecules that preferentially bind p50/p65 and/or cRel/p50 heterodimers over p50/p50 homodimers. In another aspect, the invention... Agent: Heller Ehrman LLP

20070010473 - Nucleic acid ligands to integrins: Methods are described for the isolation of nucleic acid ligands to integrins using the SELEX process. SELEX is an acronym for Systematic Evolution of Ligands by EXponential enrichment. The nucleic acid ligands of the present invention are useful as therapeutic and diagnostic agents.... Agent: Swanson & Bratschun L.L.C.

20070010472 - Oligonucleotide compositions and their use to induce differentiation of cells: The present invention provides compositions comprising a 3′-OH, 5′-OH, chemically unmodified, synthetic phosphodiester nucleotide sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, and SEQ ID NO: 4, and a pharmaceutically acceptable carrier, wherein the compositions are useful to induce... Agent: John S. Pratt, Esq Kilpatrick Stockton, LLP

20070010467 - Targeted double stranded rna mediated cell killing: A method of killing a specific target cell/tissue is disclosed. The method comprises exposing the specific target cell/tissue to a composition-of-matter comprising a double stranded RNA molecule associated with a targeting moiety selected capable of targeting to the specific target cell/tissue, thereby killing the specific target cell/tissue.... Agent: Martin Moynihan Anthony Castorina

20070010476 - Therapy and diagnosis of conditions related to telomere length and/or telomerase activity: Method and compositions are provided for the determination of telomere length and telomerase activity, as well as the ability to inhibit telomerase activity in the treatment of proliferative diseases. Particularly, primers are elongated under conditions which minimize interference from other genomic sequences, so as to obtain accurate determinations of telomeric... Agent: Perkins Coie LLP

20070010475 - Use of spongosine (2-methoxyadenosein) for the treatment of pain, in particular hyperalgesia: Use of spongosine (2-methoxyadenosine) as an analgesic, in particular for the treatment of hyperalgesia, is described.... Agent: Fish & Richardson PC

20070010477 - Acyl homoserine lactones for inhibition of cell growth: The present invention provides a method for inhibiting the growth of cancer cells using AHLs of the general formula CX-homoserine lactone where “X” represents a number of between 5 and 14 carbon atoms in the acyl chain of the AHL. The method comprises the step of administering to an individual... Agent: Hodgson Russ LLP

20070010479 - Compositions and methods for treatment of mitochondrial diseases: Compounds, compositions, and methods are provided for treatment of disorders related to mitochondrial dysfunction. The methods comprise administering to a mammal a composition containing pyrimidine nucleotide precursors in amounts sufficient to treat symptoms resulting from mitochondrial respiratory chain deficiencies.... Agent: Nixon & Vanderhye, PC

20070010478 - Zosuquidar, daunorubicin, and cytarabine for the treatment of cancer: The present invention relates to a method of treating patients with solid tumors, leukemias, and other malignancies using a combination of zosuquidar, daunorubicin, and cytarabine. The invention is also directed to pharmaceutical formulations comprising zosuquidar, daunorubicin, and cytarabine. The formulations are particularly effective in treating relapsed Acute Myelogenous Leukemia (AML).... Agent: Knobbe Martens Olson & Bear LLP

20070010480 - Dietary food items for a weight control or weight loss diet: The invention relates to dietetic foods in the context of weight control or weight reduction, comprising at least one n3 fatty acid (omega-3) in combination with dietary fibers. Advantageously, the foods further comprise a balanced ratio of carbohydrates, protein and fat. Preferably, the inventive foods comprise a balanced ratio of... Agent: Merchant & Gould PC

20070010483 - Glucocerebroside treatment of liver disorders: The present invention provides a method for the treatment of immune mediated or immune related diseases or disorders, infectious diseases, metabolic disorders and cancer in mammalian subjects. This method comprises the administration of a naturally occurring, mammalian intermediary metabolite or T cell receptor ligand, preferably a glucosylceramide, to a mammalian... Agent: Enzo Biochem, Inc.

20070010484 - Method for treating or inhibiting the effects of injuries or diseases that result in neuronal degeneration and method for promoting neurogenesis: Oligosaccharides, and in particular disaccharides, which are degradation products of chondroitin sulfate proteoglycan are effective for use in treating, inhibiting, or ameliorating the effects of injuries or diseases or disorders that result in or are caused by neuronal degeneration or of disorders resulting in mental and cognitive dysfunction. They are... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20070010482 - Polysaccharide derivatives and uses in induction of an immune response: The present invention generally provides compositions comprising a polysaccharide derivative, and methods of their preparation and use for the prevention or treatment of diseases caused by Neisseria meningitidis bacteria, particularly group B (NmB) strains, and by E. coli K1. The invention provides a de-N-acetylated PS derivative in which one or... Agent: Bozicevic, Field & Francis LLP

20070010481 - Solid state irradiation of hyaluronan-based solid preparations, its derivatives and mixtures in an unsaturated gaseous atmosphere and their use: The present invention relates to a range of new products, production of biocompatible solid compositions based on hyaluronan and its derivatives using ionizing radiation in the solid state in the presence of an unsaturated gas under specified reaction conditions and the uses thereof.... Agent: Matrix Biology Institute

20070010485 - Chemotherapeutic formulations of zosuquidar trihydrochloride and modified cyclodextrins: The present invention relates to a method of treating patients with leukemias, solid tumors, and other malignancies using chemotherapeutic agents in combination with zosuquidar that has been solubilized by a modified cyclodextrin, such as sulfobutylcyclodextrin or hydroxypropyl cyclodextrin. The invention is also directed to pharmaceutical formulations comprising zosuquidar in combination... Agent: Knobbe Martens Olson & Bear LLP

20070010486 - Chemotherapeutic formulations of zosuquidar trihydrochloride and modified cyclodextrins: The present invention relates to a method of treating patients with leukemias, solid tumors, and other malignancies using chemotherapeutic agents in combination with zosuquidar that has been solubilized by a modified cyclodextrin, such as sulfobutylcyclodextrin or hydroxypropyl cyclodextrin. The invention is also directed to pharmaceutical formulations comprising zosuquidar in combination... Agent: Knobbe Martens Olson & Bear LLP

20070010487 - Chemotherapeutic formulations of zosuquidar trihydrochloride and modified cyclodextrins: The present invention relates to a method of treating patients with leukemias, solid tumors, and other malignancies using chemotherapeutic agents in combination with zosuquidar that has been solubilized by a modified cyclodextrin, such as sulfobutylcyclodextrin or hydroxypropyl cyclodextrin. The invention is also directed to pharmaceutical formulations comprising zosuquidar in combination... Agent: Knobbe Martens Olson & Bear LLP

20070010488 - Compounds for modulating cell proliferation: Compounds that modulate cell proliferation are taught. These compounds are useful as inhibitors of abnormal cell proliferation.... Agent: Fish & NeaveIPGroup Ropes & Gray LLP

20070010489 - Cellular accumulation of phosphonate analogs of hiv protease inhibitor compounds: Phosphonate substituted compounds with HIV protease inhibitory properties having use as therapeutics and for other industrial purposes are disclosed. The compositions inhibit 5 HIV protease activity and/or are useful therapeutically for the treatment of AIDS and other antiviral infections, as well as in assays for the detection of HIV protease.... Agent: Gilead Sciences Inc

20070010490 - T-type calcium channel blockers: o

20070010491 - Ophthalmic compositions for treating ocular hypertension: This invention relates to potent potassium channel blocker compounds of Formula (I) or a formulation thereof for the treatment of glaucoma and other conditions which leads to elevated intraoccular pressure in the eye of a patient. This invention also relates to the use of such compounds to provide a neuroprotective... Agent: Merck And Co., Inc

20070010492 - Composition and method for reducing homocysteine caused by drugs containing methyl compounds: This invention relates to a method and composition of limiting homocysteine. The composition consists of a problematic drug which specifically contains at least one CH3 methyl group at one or more end(s) of its chemical structure. This problematic drug is combined in an embodiment with one or more antidotal cofactors... Agent: Robert J. Generale

20070010493 - Phospinite-imidazolines and metal complexes thereof: Compounds of the formulae (I) and (Ia) where X1 is secondary phosphino; R3 is a hydrocarbon radical having from 1 to 20 C atoms, a heterohydrocarbon radical which has from 2 to 20 atoms and at least one heteroatorn selected from the group consisting of O, S, NH and NR,... Agent: Wenderoth, Lind & Ponack, L.L.P.

20070010494 - Amino-propanol derivatives as sphingosine-1-phosphate receptor modulator: m

20070010495 - 10-hydroxy-11-dihydroprostaglandin analogs as selective ep4 agonists: D is —(CH2)n-, —X(CH2)n, or —(CH2)nX-, wherein n is from 0 to 3 and X is S or O; and E is an aromatic or heteroaromatic moiety having from 0 to 4 substituents, said substituents each comprising from 1 to 6 non-hydrogen atoms is disclosed herein. Methods, compositions, and medicaments... Agent: Allergan, Inc.

20070010496 - Process for preparing malathion for pharmaceutical use: The present invention provides a process for preparing a highly pure form of malathion having a reduced level of toxic impurities. In addition, the malathion prepared by the process of this invention is storage stable. The level of toxic impurities in the malathion, e.g., isomalathion, O,O,S-trimethyl phosphorodithioate (MeOOSPS), O,O,S-trimethyl phosphorothioate... Agent: Taro Pharmaceuticals U.s.a., Inc. C/o Venable LLP

20070010497 - Pharmaceutical composition comprising a p2x7 antagonist and sulfasalazine: The invention provides a pharmaceutical composition, pharmaceutical product or kit comprising a first active ingredient which is a P2X7 receptor antagonist, and a second active ingredient which is 2-hydroxy-5-[[4-[(2-pyridinylamino)sulfonyl]phenyl]azo]benzoic acid (sulfasalazine) or a pharmaceutically acceptable derivative thereof, for use in the treatment of inflammatory disorders.... Agent: Fish & Richardson P.C.

20070010498 - Method for reducing blood loss associated with cardio-pulmonary bypass surgery: The invention provides a method for reducing blood loss associated with cardio-pulmonary bypass surgery in a human that is about to undergo, is undergoing, or has undergone, cardio-pulmonary bypass surgery. The method comprises administering to the human an effective amount of a non-antibacterial tetracycline formulation. The non-antibacterial tetracycline formulation is... Agent: Hoffmann & Baron, LLP

20070010499 - Medicinal compositions containing aspirin: A combination of 2-acetoxy-5-(α-cyclopropylcarbonyl-2-fluorobenzyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridine or a pharmaceutically acceptable salt thereof, and aspirin, which possess excellent inhibitory activity against platelet aggregation and thrombogenesis, and is useful for preventing or treating diseases caused by thrombus or embolus.... Agent: Frishauf, Holtz, Goodman & Chick, PC

20070010500 - Prevention of ovarian cancer by administration of a vitamin d compound: The present invention relates to methods for preventing the development of epithelial ovarian cancer by administering a Vitamin D compound in an amount capable of increasing apoptosis in non-neoplastic ovarian epithelial cells of the female subject.... Agent: Jenner & Block, LLP

20070010502 - Methods and reagents for the treatment of immunoinflammatory disorders: The invention features a method for treating a patient diagnosed with, or at risk of developing, an immunoinflammatory disorder by administering to the patient a tetra-substituted pyrimidopyrimidine, either alone or in combination with one or more additional agents. The invention also features a composition containing a tetra-substituted pyrimidopyrimidine in combination... Agent: Clark & Elbing LLP

20070010501 - Skin treatments: Compositions comprising an LXR activator and retinoic acid and/or a metabolic precursor thereto are useful in reducing the effects of chronoageing and/or photoageing of the skin.... Agent: Unilever Intellectual Property Group

20070010503 - Compounds useful for treating neurodegenerative disorders: As described herein, the present invention provides compounds useful for treating or lessening the severity of a neurodegenerative disorder. The present invention also provides methods of treating or lessening the severity of such disorders wherein said method comprises administering to a patient a compound of the present invention, or composition... Agent: Choate, Hall & Stewart LLP

20070010504 - Polymorphic and amorphous salt forms of squalamine dilactate: The invention relates to select squalamine salts, methods of their synthesis, their therapeutic use and their advantages relating to manufacturing, product stability and toxicity. More specifically, this application is directed to various forms of the dilactate salt of squalamine and their utility in inhibiting neovascularization and endothelial cell proliferation.... Agent: Morgan Lewis & Bockius LLP

20070010505 - Methods of treating disease states using antiangiogenic agents: e

20070010506 - Methods of using nitroxides in conjuction with photosensitzers and sonosensitizers: The teachings herein relate to new methods of ameliorating the negative effects of a photosensitizer or sonosensitizer in a patient using a nitroxide.... Agent: Knobbe Martens Olson & Bear LLP

20070010507 - Compounds useful in the therapy of alzheimer's disease and formulations containing them: Floroglucino salts, in particular salts of tetrahydro- and octahydro-hyperforin or adhyperforin derivates and of colupon with acetylcholinesterase-inhibiting alkaloids and methods for the preparation thereof. The salts are useful for the treatment of depression and Alzheimer's disease can be administered as conventional pharmaceutical formulations or as controlled-release transdermal preparations.... Agent: Young & Thompson

20070010508 - Use of 10-hydroxy-10,11-dihydrocarbamazepine derivatives for the treatment of affective disorders: The present invention relates to a method for the treatment, including the maintenance treatment, of affective disorders, which comprises administering, especially every 20 to 28 hours, to said subject a therapeutically effective amount, especially an amount between about 500 and about 3000 mg, of a compound of formula (1) wherein... Agent: Novartis Corporate Intellectual Property

20070010509 - Cycloamine ccr5 receptor antagonists: Remedies or prophylactics for diseases in association with CCR5 such as AIDS, rheumatoid arthritis or nephritis comprising a cyclic amine compound represented by the following formula (I), a pharmaceutically acceptable acid addition salt thereof or a pharmaceutically acceptable C1-C6 alkyl addition salt thereof, as an active ingredient.... Agent: Sughrue Mion, PLLC

20070010510 - 4-substituted derivatives of pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine and uses thereof: 4-Substituted derivatives of pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine are described. Compounds are active as antitumoural agents.... Agent: Albert Wai-kit Chan Law Offices Of Albert Wai-kit Chan

20070010512 - Heterocyclic substituted 1,4-dihydro-4-oxo-1,8-naphthpyridine analogs: S

20070010511 - Organic compounds: Novel substituted piperidines of the general formulae (I) and (II) with the substituent definitions as explained in detail in the description are described. The compounds are suitable in particular as renin inhibitors and are highly potent.... Agent: Wenderoth, Lind & Ponack, L.L.P.

20070010513 - Carbon-linked substituted piperidines and derivatives thereof useful as histamine h3 antagonists: R1 is optionally substituted alkyl, alkenyl, aryl, heteroaryl, cycloalkyl or heterocycloalkyl; and the remaining variables are as defined in the specification; compositions and methods of treating allergy-induced airway responses, congestion, obesity, metabolic syndrome nonalcoholic fatty liver disease, hepatic steatosis, nonalcoholic steatohepatitis, cirrhosis, hepatacellular carcinoma or cognition deficit disorders using said... Agent: Schering-plough Corporation Patent Department (k-6-1, 1990)

20070010514 - Non-steroidal progesterone receptor modulators: a process for their preparation, the use of the progesterone receptor modulators for producing medicaments, and pharmaceutical compositions comprising these compounds. The compounds according to the invention are suitable for the therapy and prophylaxis of gynaecological disorders such as endometriosis, leiomyomas of the uterus, dysfunctional bleeding and dysmenorrhoea, and for... Agent: Millen, White, Zelano & Branigan, P.C.

20070010515 - [1,2,4] triazolo [1,5, a] pyrimidin-2-ylurea derivative and use thereof: Novel [1,2,4]triazolo[1,5-a]pyrimidine derivative of the general formula (1): (1) its prodrug or a pharmaceutically acceptable salt thereof, which exhibits an antigen presentation inhibiting activity and is useful as a preventive and/or therapeutic agent for immunological rejection and/or graft versus host reaction in organ/bone marrow transplant, autoimmune disease, allergic disease and/or... Agent: Nields & Lemack

20070010516 - Novel piperidine derivatives: The invention relates to novel piperidine derivatives and related compounds of General Formula I and their use as active ingredients in the preparation of pharmaceutical compositions. The invention also concerns related aspects including processes for the preparation of the compounds, pharmaceutical compositions containing one or more of those compounds and... Agent: Dickstein Shapiro LLP

20070010517 - Pharmaceutical salts of reboxetine: The present invention relates to novel crystalline, water-soluble salts of the 2S,3S enantiomer of reboxetine, which are the fumarate and succinate salts thereof, to a process for their preparation, to their utility in therapy and to pharmaceutical corn-positions containing them.... Agent: Warner-lambert Company

20070010518 - Method for administering levosimendan: The invention relates to intermittent administration of a levosimendan compound or a pharmaceutically acceptable salt thereof in the treatment of cardiovascular disorders such as chronic heart failure. The intermittent dose is more than 0.04 mg/kg and the period between each intermittent dose is 6-30 days, preferably 6-25 days. The administration... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20070010519 - New pyridazines as 11b-hsd1 inhibitors: e

20070010520 - Triazolopyrazines and methods of making and using the same: The invention is based on the discovery that compounds of formula (I) possess unexpectedly high affinity for the A2a adenosine receptor, and can be useful as antagonists thereof for preventing and/or treating numerous diseases, including Parkinson's disease. In one embodiment, the invention features a compound of formula I (See formula... Agent: Biogen Idec Inc Patent And Trademark Coordinator

20070010521 - Condensed polycyclic compounds: e

20070010523 - Azaindazole compounds and methods of use: Compounds are provided that act as potent antagonists of the CCR1 receptor, and have in vivo anti-inflammatory activity. The compounds are generally aryl piperazine derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR1-mediated diseases, and as controls in assays for the identification of competitive CCR1 antagonists.... Agent: Townsend And Townsend And Crew, LLP

20070010524 - Azaindazole compounds and methods of use: Compounds are provided that act as potent antagonists of the CCR1 receptor, and have in vivo anti-inflammatory activity. The compounds are generally aryl piperazine derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR1-mediated diseases, and as controls in assays for the identification of competitive CCR1 antagonists.... Agent: Townsend And Townsend And Crew, LLP

20070010525 - Method and compositions for modulating neuropeptide hormone secretion: Methods for increasing the release of oxytocin or vasopressin or both from the posterior pituitary of a mammal in need thereof, comprising administering to the mammal an effective amount of a cyclic guanosine 3′,5′-monophosphate phosphodiesterase type five (cGMP PDE5) inhibitor to the mammal. The method is particularly useful to treat... Agent: Baker Donelson Bearman Caldwell & Berkowitz, PC

20070010522 - Triazolo[1,5-c]pyrimidines and pyrazolo[1,5-c]pyrimidines useful as a2a adenosine receptor antagonists: The invention is based on the discovery that compounds of formula (I) possess unexpectedly high affinity for the A2a adenosine receptor, and can be useful as antagonists thereof for preventing and/or treating numerous diseases, including Parkinson's disease. In one embodiment, the invention features a compound of formula (I).... Agent: Biogen Idec Inc Patent And Trademark Coordinator

20070010526 - Therapeutic isoquinoline compounds: Provided herein is a compound of the formula (I), wherein said compounds are useful for the treatment of psychiatric disorders including but not limited to depression, generalized anxiety, eating disorders, dementia, panic disorder, and sleep disorders. The compounds may also be useful in the treatment of gastrointestinal disorders, cardiovascular regulation,... Agent: Astra Zeneca Pharmaceuticals Lp Global Intellectual Property

20070010527 - 4-anilino-3-quinolinecarbonitriles for the treatment of cancer: o

20070010528 - Thiazoline derivative and use of the same:

20070010529 - Nitrogenous heterocyclic compounds and medical use thereof: (wherein all the symbols have the same meanings as defined in the above description) and a production method and use thereof. The compounds represented by formula (I), or its salt, N-oxide or solvate, or a prodrug thereof have p38 MAP kinase inhibitory activity, and are useful in the prevention and/or... Agent: Wenderoth, Lind & Ponack, L.L.P.

20070010530 - Substituted pyrazoles: Substituted pyrazoles, methods of manufacturing them, compositions containing them, and methods of using them to treat, for example, autoimmune diseases mediated by cathepsin S.... Agent: Philip S. Johnson Johnson & Johnson

20070010531 - Substituted pyrazole compounds: Compounds of the formula (I) and salts and solvates thereof, in which X, R1, R2, R3, and R5 have the meanings indicated in claim 1, are suitable as ligands of 5 HT receptors.... Agent: Millen, White, Zelano & Branigan, P.C.

20070010532 - 3-pyridylcarboxamide derivatives as pesticidal agents: The invention relates to a 3- pyridylcarboxamide derivative of formula (I): wherein the various symbols are as defined in the description, to compositions thereof, to their use for the control of pests, and to processes for their preparation.... Agent: Sterne, Kessler, Goldstein & Fox PLLC

20070010533 - Compounds, methods and compositions useful for the treatment of bovine viral diarrhea virus (bvdv) infection and hepatitis c virus (hcv) infection: The present invention relates to novel compounds and methods that are useful in treating members of the Flaviviridae family of viruses. Compounds of the present invention will have a structure according to Formulas (I)-(VI) as recited throughout the application.... Agent: Jenkins, Wilson, Taylor & Hunt, P. A.

20070010534 - Novel compounds: The present invention is directed to novel compounds of Formula (I) for use in the treatment of diseases, in a mammal, in which inappropriate, excessive or undesirable angiogenesis has occurred and/or where excessive Tie2 receptor activity has occurred.... Agent: Smithkline Beecham Corporation Corporate Intellectual Property-us, Uw2220

20070010535 - Antagonists of the magnesium binding defect as therapeutic agents and methods for treatment of abnormal physiological atates: This invention provides a class of therapeutic compounds and methods for the treatment of mammals with physiological disorders, such as for example a frequently occurring type of essential hypertension, which are critically associated with the decreased binding of magnesium to the plasma membranes of their cells. These methods consist of... Agent: Stinson Morrison Hecker LLP Attn: Patent Group

20070010536 - Novel class of cytodifferentiating agents and histone deacetylase inhibitors, and methods of use thereof: wherein each of R1 and R2 is, substituted or unsubstituted, aryl, cycloalkyl, cycloalkylamino, naphtha, pyridineamino, piperidino, t-butyl, aryloxy, arylalkyloxy, or pyridine group; wherein A is an amido moiety, —O—, —S—, —NH—, or —CH2—; and wherein n is an integer from 3 to 8. The present invention also provides a method... Agent: Mintz Levin Cohn Ferris Glovsky & Popeo

20070010537 - Fused pyramidine derivative and use thereof: e

20070010538 - Inhibition of pathogenic processes related to tissue trauma: According to the present invention compositions and methods are provided to prevent the pathogenic aspects of tissue trauma while preserving normal tissue repair mechanisms, based on the fact that these molecules abrogate the cascade of damage initiated by tissue trauma, while maintaining this the requisite healthy extracellular matrix economy. The... Agent: Fish & NeaveIPGroup Ropes & Gray LLP

20070010539 - Substituted 8'-pyri(mi)dinyl-dihydrospiro-[cycloalkylamine]-pyrimido[1,2-a]pyrimidin-6-one derivatives: wherein X, Y, R1, R2, R3, R4, o, m, n, p and q are as defined herein. The invention relates also to a medicament comprising the said derivative or a salt thereof as an active ingredient which is used for preventive and/or therapeutic treatment of a neurodegenerative disease caused by... Agent: Ross J. Oehler Sanofi-aventis U.s. LLC

20070010540 - Crystal structure of liganded cfms kinase domain: A crystal structure of the cfms kinase domain, co-crystal structure with a bound small molecule, as well as methods of using the same in the discovery of cfms inhibitors and in the treatment of diseases mediated by inappropriate cfms activity.... Agent: Glaxosmithkline Corporate Intellectual Property, Mai B475

20070010541 - Methods for treating vascular diseases: The invention includes methods of treating or preventing vascular disease or promoting vascular growth or development. The methods can be used in the treatment of diseases associated with ischemia, such as heart attack and stroke.... Agent: Clark & Elbing LLP

20070010542 - Benzimidazole compound: R4, R5, R6 and R7 represent a hydrogen atom, halogen atom, C1-C6 alkyl group, C1-C6 haloalkyl group, C1-C6 alkoxy group or C1-C6 haloalkoxy group; and W1 represents a single bond, methylene or ethylene group, a salt thereof or a solvate of these.... Agent: Birch Stewart Kolasch & Birch

20070010543 - Compositions and methods for treating gastrointestinal hypomotility and associated disorders: This invention relates to methods for treating, preventing and/or managing GI hypomotility or a disorder associated with GI hypomotility in a subject including administering to the subject two compounds, where the first compound is a 5HT3 agonist and where the combination of the two compounds results in an increase in... Agent: Lahive & Cockfield, LLP

20070010544 - Abca1 elevating compounds: The present invention provides compounds useful for increasing cellular ATP binding cassette transporter ABCA1 production in mammals, and to methods of using such compounds in the treatment of coronary artery diseases, dyslipidiemias and metabolic syndrome. The invention also relates to methods for the preparation of such compounds, and to pharmaceutical... Agent: J. Elin Hartrum Cv Therapeutics, Inc.

20070010546 - Method for enhancing epithelial cell proliferation and uses thereof: The present invention is directed to uses of GM-284 for enhancing epithelial cell proliferation. The present invention is also provides methods for treating a keratinocyte-associated disorder in a subject in need of treatment.... Agent: Sander Rabin Md Jd Convergent Technology Patent Law Group

20070010547 - Method for modulating gene expression in epithelial cells: The present invention is directed to methods for modulating gene expression in an epithelial cell.... Agent: Sander Rabin Md Jd Convergent Technology Patent Law Group

20070010545 - Solid forms of a chemokine receptor antagonist and methods of use thereof: The citrate salt of (S)-4-(4-Chloro-phenyl)-1-{3-[7-(1-hydroxy-1-methyl-ethyl)-11H-10-oxa-1-aza-dibenzo[a,d]cyclohepten-5-ylidene]-propyl}-3,3-dimethyl-piperidin-4-ol, which may be used in pharmaceutical applications, is disclosed. The crystalline Citrate Salt, including particular single crystal forms and combinations of the single crystalline forms, are also discussed. Mixtures for forming the crystalline salts are discussed. As well, methods of producing the Citrate Salt, and... Agent: Millennium Pharmaceuticals, Inc.

20070010548 - Compounds having inhibitive activity of phosphatidylinositol 3-kinase and methods of use thereof: Compounds inhibiting phosphatidylinositol 3-kinase (PI 3-K) activities and methods of preparing and using thereof in treating diseases are disclosed. Compounds inhibiting PI 3-K activity and methods of using PI 3-K inhibitory compounds to inhibit cancer cell grwoth or to treat disorders of immunity and inflammation, in which PI 3-K plays... Agent: C. Irvin Mcclelland Oblon, Spivak, Mcclelland, Maier & Neustadt, P.C.

20070010549 - Imidazo(4,5-b)pyridine-derivatives as inducible no-synthase inhibitors: m

20070010550 - Scopolamine to reduce or eliminate hot flashes, night sweats, and insomnia: Compositions and methods of treating or preventing hot flashes, night sweats, and/or insomnia in a subject that involve scopolamine are disclosed. For example, methods of treating hot flashes, night sweats, and/or insomnia in a subject that involve transdermal delivery of scopolamine are set forth herein.... Agent: Monica A. De La Paz Fulbright & Jaworski L.L.P.

20070010552 - Fluorinated heterocyclic compounds and methods of synthesis: Compositions of the present invention comprise fluorinated heterocyclic compounds, including monofluoroflosequinan and difluoroflosequinan. The methods of the present invention comprise the synthesis of monofluoroflosequinan and difluoroflosequinan.... Agent: Medlen & Carroll, LLP

20070010551 - Quinoline derivatives as neutrophil elastase inhibitors and their use: There are provided novel compounds of formula (I) wherein R1, R3, R4, R5, G1, G2, L and n are as defined in the Specification and optical isomers, racemates and tautomers thereof, and pharmaceutically acceptable salts thereof; together with processes for their preparation, compositions containing them and their use in therapy.... Agent: Fish & Richardson P.C.

20070010553 - New use: The present invention relates to the use of metabotropic glutamate receptor 5 (mGluR5) antagonists for the treatment or prevention of cough.... Agent: Birch, Stewart, Kolasch & Birch, LLP

20070010554 - Aryl substituted pyridines and the use thereof: or a pharmaceutically acceptable salt, prodrug or solvate thereof, wherein Ar and R1—R4 are set in the specification. The invention is also directed to the use of compounds of Formula I for the treatment of neuronal damage following global and focal ischemia, for the treatment or prevention of neurodegenerative conditions... Agent: Sterne, Kessler, Goldstein & Fox PLLC

20070010555 - Indazole having analgesic activity:

20070010556 - Thiophene derivatives as chk 1 inhibitors: This invention relates to novel compounds having the structural formula (I) and to their pharmaceutical compositions and to their methods of use. These novel compounds provide a treatment or prophylaxis of cancer.... Agent: Astrazeneca R&d Boston

20070010557 - Novel amides useful for treating pain: i

20070010559 - Indole derivatives for use as chemical uncoupler: Novel 3-vinylsulfonyl indole derivatives are chemical uncouplers useful e.g. for treatment of obesity.... Agent: Novo Nordisk, Inc. Patent Department

20070010558 - Opioid receptor antagonists: A compound of the formula (I) wherein the variables X1 to X5, R1 to R7 including R3′, E, q, v, y, z, A and B are as described, or a pharmaceutically acceptable salt, solvate, enantiomer, racemate, diastereomer or mixtures thereof, useful for the treatment, prevention or amelioration of obesity and... Agent: Eli Lilly & Company

20070010560 - Benzimidazole derivatives as raf kinase inhibitors: The present invention relates to benzimidazole derivatives of formula I, the use of the compounds of formula I as inhibitors of one or more kinases, the use of the compounds of formula I for the manufacture of a pharmaceutical composition and a method of treatment, comprising administering said pharmaceutical composition... Agent: Heller Ehrman White & Mcauliffe LLP

20070010561 - Prenylation inhibitors and methods of their synthesis and use: The present invention is directed to compounds useful in the treatment of diseases associated with prenylation of proteins and pharmaceutically acceptable salts thereof, to pharmaceutical compositions comprising same, and to methods for inhibiting protein prenylation in an organism using the same.... Agent: Sheridan Ross PC

20070010562 - Nr1h4 nuclear receptor binding compounds: The present invention relates to compounds according to the general formula (1) which bind to the NR1H4 receptor and act as agonists, antagonists or mixed agonists/antagonists of the NR1H4 receptor. The invention further relates to the treatment of diseases and/or conditions through binding of said nuclear receptor by said compounds... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20070010563 - Novel methods for the treatment of inflammatory diseases: Methods of inhibiting the cytokine or biological activity of Macrophage Migration Inhibitory Factor (MIF) comprising contacting MIF with a compound of formula (I) are provided. The invention also relates to methods of treating diseases or conditions where MIF cytokine or biological activity is implicated comprising administration of compounds of formula... Agent: King & Spalding LLP

20070010564 - Heteroarylethenyl derivatives, their manufacture and use as pharmaceutical agents: t

20070010565 - New thiazolidinones without basic nitrogen, their production and use as pharmaceutical agents:

20070010566 - Thiazolidinones without basic nitrogen, their production and use as pharmaceutical agents:

20070010567 - Stable, neutral ph, voc-free biocidal compositions of 1,2-benzisothiazolin-3-one: What is described herein is a neutral pH, VOC-free biocidal composition of 1,2-benzisothiazolin-3-one which is stable at low temperatures for an extended period of time. The compositions are particularly advantageous in use in protecting latex, paint, coating, cosmetic and personal care formulations against microbiological spoilage.... Agent: International Specialty Products William J. Davis, Esq.

20070010568 - Substituted azabicyclo hexane derivatives as muscarinic receptor antagonists: This invention relates to derivatives of substituted azabicyclo hexanes. The compound of this invention can function as muscarinic receptor antagonists, and can be used for the treatment of various diseases of the respiratory, urinary and gastrointestinal systems mediated through muscarinic receptors. The invention also relates to a process for the... Agent: Ranbaxy Inc.

20070010570 - Medical compositions for intravesical treatment of bladder cancer: Anti-cancer coating compositions comprising 3-hydroxymethyl-5-aziridinyl-1-1-methyl-2-[1H-indole-4,7-dione]propenol (E09) are disclosed. More specifically, the coating compositions comprise EO9 and a formulation vehicle. The formulation vehicle improves the solubility and stability of EO9. Additionally, the coating compositions can include coating agents that provide better adhesion of the coating composition to the bladder wall during... Agent: Preston Gates & Ellis LLP

20070010569 - Pyrrole substituted 2-indolinone protein kinase inhibitors: The present invention relates to pyrrole substituted-2-indolinone compounds and their pharmaceutically acceptable salts which modulate the activity of protein kinases and therefore are expected to be useful in the prevention and treatment of protein kinase related cellular disorders such as cancer.... Agent: Pfizer Inc

20070010573 - Methods and compositions for treating amyloid-related diseases: Methods, compounds, pharmaceutical compositions and kits are described for treating or preventing amyloid-related disease.... Agent: Lahive & Cockfield, LLP

20070010571 - Nitrosated and nitrosylated cardiovascular compounds, compositions and methods of use: The invention describes novel nitrosated and/or nitrosylated cardiovascular compounds or pharmaceutically acceptable salts thereof, and novel compositions comprising at least one nitrosated and/or nitrosylated cardiovascular compound, and, optionally, at least one nitric oxide donor and/or at least one therapeutic agent. The invention also provides novel compositions and kits comprising at,least... Agent: Wilmerhale/nitromed

20070010572 - Novel method for the synthesis of perindopril and the pharmaceutically-acceptable salts thereof: e

20070010574 - Use of a trpm8-activating substance for the treatment of tumours: The invention relates to the use of a TRPM8-activating substance for producing a pharmaceutical composition for the treatment of tumor diseases in which TRPM8 is over-expressed.... Agent: Mayer & Williams PC

20070010575 - Intracorporeal medicaments for photodynamic treatment of disease: New intracorporeal photodynamic medicaments and certain medical uses and methods for use of such photodynamic medicaments for treatment of disease in human or animal tissue are described, wherein a primary active component of such medicaments is a halogenated xanthene or halogenated xanthene derivative. In preferred embodiments, such medicaments are used... Agent: Cook, Alex, Mcfarron, Manzo, Cummings & Mehler Ltd

20070010576 - Bycyclic tetrahydrofuran derivatives and process for the preparation thereof: w

20070010577 - Targeted atherosclerosis treatment: This invention relates generally to methods for ameliorating at least one symptom or aspect of atherosclerosis. The methods include administration of targeted carrier compositions comprising a therapeutic agent effective in ameliorating at least one aspect of atherosclerosis coupled to a targeting ligand effective is targeting the therapeutic agent to tissue... Agent: Morrison & Foerster LLP

20070010578 - Methods for qt interval control: wherein phenyl is substituted at X with one to five halogen atoms selected from the group consisting of fluorine, chlorine, bromine and iodine; and, R1, R2, R3, R4, R5 and R6 are independently selected from the group consisting of hydrogen and C1-C4 alkyl; wherein C1-C4 alkyl is optionally substituted with... Agent: Philip S. Johnson Johnson & Johnson

20070010579 - Copper salts of organic acids and use thereof as fungicides: Compounds are described, having general formula (I): A·Cu wherein A represents the bibasic ion of an organic acid which can have the meanings (A1)-(A8) and Cu represents the copper 2+ ion; and the use of compounds having formula (I), individually or in a mixture, for the control of bacterial and... Agent: Hedman & Costigan P.C.

20070010580 - Formulation for chemical peeling: The present invention refers to a new formulation able to increase the efficacy and the tolerability of preparations based on the use of compounds used to carry out chemical peeling. More particularly, the present invention refers to a composition for chemical peeling, comprising at least one keratolytic agent and dimethyl... Agent: Shoemaker And Mattare, Ltd

20070010581 - Use of 2,5-dihydroxybenzenesulfonic compounds for the treatment of disorders based on an impairment of no production and/or of regulation of edhf function: The present invention relates to the use of 2,5-dihydroxybenzenesulfonic compounds for the manufacture of medicament for the regulation of nitric oxide (NO) synthesis and/or the regulation of EDHF (Endothelium-derived-Hyperpolarizing-Factor) in the endothelium of humans or animals, whereby the medicament is administered in a daily dose of the 2,5-dihydroxybenzenesulfonic compounds of... Agent: Perman & Green

20070010582 - Use of n-chlorotaurine for treatment of oozing tissue deficiencies: A pharmaceutical composition containing N-chlorotaurine is administered to a mammal to treat oozing tissue deficiencies.... Agent: Proskauer Rose LLP Patent Department

20070010583 - Methods and compositions for reducing blood homocysteine levels: The invention provides methods for reducing blood homocysteine levels in mammals, and treating or preventing diseases associated with elevated blood homocysteine levels, such as cardiovascular diseases and cognitive disorders. The invention also provides nutritional and pharmaceutical compositions comprising 2-hydroxy-4-(thiomethyl)-butanoic acid, including esters, analogs, derivatives or complex thereof.... Agent: Palmer & Dodge, LLP Kathleen M. Williams

20070010584 - Compositions and methods for orthostatic intolerance: The present invention relates to compositions and methods for treating orthostatic intolerance in a subject in need thereof. Methods involve, e.g., administering an amount of a norepinephrine precursor, whereby said amount is effective for treating orthostatic intolerance. A useful norepinephrine precursor is threo-3-(3,4-dihydroxyphenyl) serine (L-threo-DOPS), a derivative thereof, or a... Agent: Millen, White, Zelano & Branigan, P.C.

20070010585 - Acid addition salt of carbasugar amine derivative: (R8 to R12 each independently represents an alkyl group, an alkenyl group, an alkynyl group, an acyl group, an aryl group or an aralkyl group), with the proviso that both R1 and R2 are not a hydrogen atom at the same time; R3, R4 and R7 each independently represents a... Agent: C. Irvin Mcclelland Oblon, Spivak, Mcclelland, Maier & Neustadt, P.C.

20070010586 - Enhanced tuburculocidal activity and decreased fumes from glutaraldehyde disinfectant using acetate salts and alcohol: The addition of alcohol plus acetate salts unexpectedly enhanced the tuberculocidal activity of glutaraldehyde, and decreased the fumes of glutaraldehyde from the formula of a high-level disinfectant.... Agent: Mckee, Voorhees & Sease, P.L.C

  
01/04/2007 > 157 patent applications in 101 patent subcategories. USPTO class patent listing
Previous industry: Perfume compositions
Next industry: Colloid systems and wetting agents; subcombinations thereof; processes of


######

RSS FEED for 20141002: xml
Integrate FreshPatents.com into your RSS reader/aggregator or website to track weekly updates.
For more info, read this article.

######

Thank you for viewing Drug, bio-affecting and body treating compositions patents on the FreshPatents.com website. These are patent applications which have been filed in the United States. There are a variety ways to browse Drug, bio-affecting and body treating compositions patent applications on our website including browsing by date, agent, inventor, and industry. If you are interested in receiving occasional emails regarding Drug, bio-affecting and body treating compositions patents we recommend signing up for free keyword monitoring by email.



Results in 2.93726 seconds

PATENT INFO